aldosterone has been researched along with Cardiovascular Diseases in 289 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leptin appears as a new direct regulator of adrenal aldosterone production and leptin-mediated aldosterone production is a novel candidate mechanism underlying obesity-associated hypertension, particularly in females." | 8.98 | The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease. ( Belin de Chantemèle, EJ; Bruder-Nascimento, T; Faulkner, JL, 2018) |
| " Most of the deleterious actions of the RAAS on insulin sensitivity appear to be mediated through activation of the Angiotensin II (Ang II) Receptor type 1 (AT(1)R) and increased production of mineralocorticoids." | 8.85 | Role of aldosterone and angiotensin II in insulin resistance: an update. ( Lastra-González, G; Lastra-Lastra, G; Manrique-Acevedo, C; Restrepo-Erazo, K; Sowers, JR, 2009) |
| "To assess the impact of hyperthyroidism on aldosterone levels and myocardial oxidative status, inflammatory and fibrotic markers in hyperthyroid rats, and to test if the use of spironolactone (an aldosterone antagonist) attenuates these changes." | 7.96 | The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats. ( Aljohmani, AI; Alzoubi, KH; Mayyas, FA, 2020) |
| "We hypothesized that nicotine would ameliorate insulin resistance (IR) that is accompanied by decreased cardiac glycogen synthase kinase-3 (GSK-3) and plasminogen activator inhibitor-1 (PAI-1)." | 7.88 | Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy. ( Michael, OS; Olatunji, LA, 2018) |
| "To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome." | 7.85 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017) |
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 6.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| " The observation of reduced nitric oxide bioavailability in hyperaldosteronism implied the generation of oxidative stress by aldosterone." | 6.48 | Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. ( Queisser, N; Schupp, N, 2012) |
| "In addition, insulin resistance is not limited to classic insulin-sensitive tissues such as skeletal muscle, but it also affects the cardiovascular system, where it participates in the development of CVD and CKD." | 6.46 | Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. ( Dhuper, S; Johnson, MS; Lastra, G; Sowers, JR, 2010) |
| "With the use of ACE-inhibitors in the treatment of hypertension and heart failure, less attention has been paid to aldosterone." | 6.41 | [Aldosterone and cardiovascular diseases, more than water and salt retention]. ( Duprez, D, 2002) |
| "Primary aldosteronism is the most frequent secondary hypertensive disease and is characterized by an elevated risk for cardiovascular disease." | 5.91 | Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism. ( Fujiwara, A; Haruna, A; Haze, T; Hirawa, N; Kawano, R; Kobayashi, Y; Ohki, Y; Ozawa, M; Saka, S; Suzuki, S; Tamura, K, 2023) |
| "Patients with primary aldosteronism (PA) have a higher risk of cardiovascular disease (CVD) than essential hypertension due to underlying hyperaldosteronism." | 5.91 | High plasma aldosterone concentration is associated with worse 24-h ambulatory blood pressure profile in patients with primary aldosteronism. ( Azushima, K; Haze, T; Kanaoka, T; Kinguchi, S; Kobayashi, K; Kobayashi, R; Morita, R; Sunohara, S; Tamura, K; Toya, Y; Wakui, H, 2023) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 5.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "All primary aldosteronism patients were diagnosed by autonomous aldosterone secretion using confirmatory tests, and then divided into nPA (n = 130) and primary aldosteronism patients with high PAC (hPA: n = 162) using a PAC cutoff level of less than 443 pmol/l (16 ng/dl), representing the normal upper limit of PAC." | 5.46 | Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. ( Hamasaki, T; Hashimoto, K; Hayashi, RD; Kajimoto, Y; Kitamura, T; Kouhara, H; Kurebayashi, S; Mukai, K; Murata, M; Nakao, M; Otsuki, M; Shimomura, I; Takeiri, S; Tamada, D; Yamamoto, T, 2017) |
| "Primary hyperparathyroidism is associated with an increased cardiovascular morbidity and mortality." | 5.35 | Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. ( Alrasheedi, S; Ayav, A; Bresler, L; Brunaud, L; Caillard, C; Germain, A; Mirallie, E; Rancier, M; Weryha, G; Zarnegar, R, 2009) |
| "Aldosterone levels were significantly increased (P < 0." | 5.33 | Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. ( Cascella, T; Colao, A; Di Biase, S; Giallauria, F; Labella, D; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Tauchmanovà, L; Vigorito, C, 2006) |
| "Angiotensinogen (AGT) and aldosterone play key roles in the regulation of blood pressure and are implicated in the pathogenesis of cardiovascular diseases." | 5.12 | DNA Methylation of the Angiotensinogen Gene, ( Demura, M; Takeda, Y; Yoneda, T, 2021) |
| "Leptin appears as a new direct regulator of adrenal aldosterone production and leptin-mediated aldosterone production is a novel candidate mechanism underlying obesity-associated hypertension, particularly in females." | 4.98 | The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease. ( Belin de Chantemèle, EJ; Bruder-Nascimento, T; Faulkner, JL, 2018) |
| " Hyperaldosteronism due to klotho deficiency results in vascular calcification, which can be mitigated by spironolactone treatment." | 4.90 | Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. ( Fahrleitner-Pammer, A; Gaksch, M; Grübler, M; Kienreich, K; Kraigher-Krainer, E; März, W; Mrak, P; Pieske, B; Pilz, S; Ritz, E; Rus-Machan, J; Tomaschitz, A; Toplak, H; Verheyen, N, 2014) |
| " Most of the deleterious actions of the RAAS on insulin sensitivity appear to be mediated through activation of the Angiotensin II (Ang II) Receptor type 1 (AT(1)R) and increased production of mineralocorticoids." | 4.85 | Role of aldosterone and angiotensin II in insulin resistance: an update. ( Lastra-González, G; Lastra-Lastra, G; Manrique-Acevedo, C; Restrepo-Erazo, K; Sowers, JR, 2009) |
| " However, although aldosterone receptor antagonism reduces mortality in patients with congestive heart failure, the progestational and antiandrogenic side effects of the nonspecific aldosterone receptor antagonist, spironolactone, have limited its usefulness in the treatment of hypertension." | 4.82 | Eplerenone: cardiovascular protection. ( Brown, NJ, 2003) |
| "Eplerenone is a selective aldosterone blocker that effectively lowers BP in both white and black patients with hypertension and provides meaningful further antihypertensive efficacy when added to patients whose hypertension is inadequately controlled by angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers." | 4.81 | Clinical implications of aldosterone blockade. ( Weber, MA, 2002) |
| " The therapeutic efficacy of spironolactone (Pharmacia Corp) in severe chronic heart failure is established." | 4.81 | The role of aldosterone receptor blockade in the management of cardiovascular disease. ( Krum, H; Liew, D, 2002) |
| "To assess the impact of hyperthyroidism on aldosterone levels and myocardial oxidative status, inflammatory and fibrotic markers in hyperthyroid rats, and to test if the use of spironolactone (an aldosterone antagonist) attenuates these changes." | 3.96 | The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats. ( Aljohmani, AI; Alzoubi, KH; Mayyas, FA, 2020) |
| "We hypothesized that nicotine would ameliorate insulin resistance (IR) that is accompanied by decreased cardiac glycogen synthase kinase-3 (GSK-3) and plasminogen activator inhibitor-1 (PAI-1)." | 3.88 | Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy. ( Michael, OS; Olatunji, LA, 2018) |
| "To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome." | 3.85 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017) |
| "The leukocyte-derived myeloperoxidase (MPO), the nitric oxidase synthase (NOS) inhibitor asymmetrical dimethyl-arginine (ADMA) and the renin-angiotensin-aldosterone-system (RAAS) are associated with cardiovascular diseases (CVD)." | 3.85 | Myeloperoxidase, asymmetric dimethyl-arginine and the renin-angiotensin-aldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. ( Enko, D; März, W; Meinitzer, A; Pilz, S; Tomaschitz, A; Zelzer, S, 2017) |
| "These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism." | 3.85 | Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder. ( Kim, IK; Olatunji, LA; Seok, YM; Usman, TO, 2017) |
| "Thirty-three consecutive patients with essential hypertension and hypovitaminosis D underwent therapy with cholecalciferol 50 000 IU/week orally for 8 weeks." | 3.83 | Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D. ( Bacca, A; Bernini, G; Bruno, RM; Carrara, D; Duranti, E; Ghiadoni, L; Taddei, S, 2016) |
| "Patients with cirrhosis and refractory ascites without renal dysfunction had systemic hemodynamics, renal function, and neurohormones (plasma active renin, aldosterone, norepinephrine and angiotensin II) measured pre- and 6 days post-paracentesis." | 3.83 | Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. ( James, PD; Tan, HK; Wong, F, 2016) |
| "Hyperhomocysteinemia, neurohormonal activation, inflammation and altered fibrinolysis have been linked to atherothrombosis as well as to myocardial fibrosis and heart failure." | 3.75 | Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. ( Benjamin, EJ; D'Agostino, RB; Hayes, L; Jacques, P; Joseph, J; Levy, D; Pencina, MJ; Selhub, J; Tofler, GH; Vasan, RS; Wang, TJ, 2009) |
| "Primary aldosteronism is associated with an increased risk of cardiovascular disease and kidney dysfunction compared to essential hypertension." | 3.01 | The Effect of Aldosterone on Cardiorenal and Metabolic Systems. ( Abe, M; Kobayashi, H; Otsuka, H, 2023) |
| "Emerging antenatal risk factors such as preeclampsia appear to increase the risk of hypertension and cardiovascular disease across the life course in both the offspring and women after pregnancy." | 3.01 | Appraising the Preclinical Evidence of the Role of the Renin-Angiotensin-Aldosterone System in Antenatal Programming of Maternal and Offspring Cardiovascular Health Across the Life Course: Moving the Field Forward: A Scientific Statement From the American ( Alexander, BT; August, P; Bertagnolli, M; Ferranti, EP; Grobe, JL; Jones, EJ; Loria, AS; Safdar, B; Sequeira-Lopez, MLS; South, AM, 2023) |
| "5 mg (n=27), 25 mg (n=26), or 50 mg (n=25) daily for 36 weeks in a double-blind, placebo-controlled, multiple dosage trial to assess safety, tolerability and feasibility and to explore cardiovascular efficacy." | 2.90 | Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. ( Anderson, AH; Charytan, DM; Dember, LM; DiCarli, M; Himmelfarb, J; Hsu, JY; Hung, AM; Ikizler, TA; Kimmel, PL; Kliger, AS; Landis, JR; Mehrotra, R; Raj, DS; Sharma, S; Skali, H; Weiner, DE; Williams, M, 2019) |
| "Primary aldosteronism (PA), the most common form of secondary hypertension, has been considered for decades as a "benign" form of hypertension, but evidences progressively built up to show that patients with PA had an excess rate of cardiovascular damage as compared to blood pressure-matched essential hypertensive patients." | 2.72 | The cardiovascular consequences of hyperaldosteronism. ( Cesari, M; Maiolino, G; Rossi, GP; Seccia, TM, 2021) |
| "Conn, primary aldosteronism (PA) today is well established as a relevant cause of secondary hypertension and accounts for about 5-10 % of hypertensives." | 2.66 | Salt Appetite and its Effects on Cardiovascular Risk in Primary Aldosteronism. ( Adolf, C; Handgriff, L; Heinrich, DA; Reincke, M; Schneider, H, 2020) |
| "Aldosterone is a mineralocorticoid hormone that participates in the regulation of electrolyte balance, blood pressure, and tissue remodeling." | 2.61 | Endothelial Dysfunction in Primary Aldosteronism. ( Chen, ZW; Chou, CH; Hung, CS; Liao, CW; Lin, YH; Pan, CT; Tsai, CH; Wu, VC, 2019) |
| "Aldosterone displays powerful vascular effects and acts as a potent pro-fibrotic agent in cardiovascular remodeling." | 2.58 | Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease. ( Armani, A; Caprio, M; Gorini, S; Mammi, C; Marzolla, V, 2018) |
| "Moreover, primary aldosteronism patients are exposed to an increased risk of cardio and cerebrovascular events and metabolic comorbidities compared with patients affected by essential hypertension." | 2.58 | Primary aldosteronism in the primary care setting. ( Buffolo, F; Monticone, S; Mulatero, P; Tetti, M, 2018) |
| "A aldosterone is a component of the renin-angiotensin-aldosterone system, classically known for its role in sodium and water retention." | 2.50 | Aldosterone: a cardiometabolic risk hormone? ( Bressan, J; Eloiza Priore, S; Feliciano Pereira, P, 2014) |
| "Studies in primary aldosteronism, congestive heart failure, and chronic kidney disease have identified associations between hyperaldosteronism, hyperparathyroidism, and bone loss, which appear to improve when inhibiting the RAAS." | 2.50 | Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. ( Brown, JM; Vaidya, A, 2014) |
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 2.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| "The MR-associated hypertension is classified into two subtypes, that with elevated plasma aldosterone levels and that with normal plasma aldosterone levels." | 2.48 | Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. ( Itoh, H; Shibata, H, 2012) |
| "In the setting of primary aldosteronism, renal and faecal calcium loss triggers increased PTH secretion which in turn aggravates aldosterone secretion and CV damage." | 2.48 | Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. ( Drechsler, C; Fahrleitner-Pammer, A; Horina, JH; Kienreich, K; März, W; Ofner, M; Pieber, TR; Pieske, B; Pilz, S; Ritz, E; Tomaschitz, A, 2012) |
| " The observation of reduced nitric oxide bioavailability in hyperaldosteronism implied the generation of oxidative stress by aldosterone." | 2.48 | Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. ( Queisser, N; Schupp, N, 2012) |
| "Addition of MR antagonists to standard treatment for hypertension and cardiac or renal disease decreases end-organ pathology and sympathetic nerve activation (SNA), and increases quality of life indices." | 2.48 | The ubiquitous mineralocorticoid receptor: clinical implications. ( Gomez-Sanchez, CE; Gomez-Sanchez, CM; Gomez-Sanchez, EP; Hawkins, UA, 2012) |
| "Primary hyperaldosteronism, representing one tenth of hypertensive patients, is an under-diagnosed disease partly because of difficult diagnostic steps and absence of standard criteria." | 2.48 | [Update on endocrine hypertension]. ( Al-Salameh, A; Chanson, P; Cohen, R; Plouin, PF, 2012) |
| "Aldosterone has a number of non-classical, mineralocorticoid receptor (MR)-mediated actions, including tissue remodeling, modulation of vascular tone and stimulating inflammation and fibrosis, which may fuel progression of end organ damage." | 2.47 | Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. ( Bakker, SJ; de Vries, LV; Hillebrands, JL; Laverman, GD; Navis, G; van Goor, H; Waanders, F, 2011) |
| "In addition, insulin resistance is not limited to classic insulin-sensitive tissues such as skeletal muscle, but it also affects the cardiovascular system, where it participates in the development of CVD and CKD." | 2.46 | Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. ( Dhuper, S; Johnson, MS; Lastra, G; Sowers, JR, 2010) |
| "Animal models for human idiopathic hyperaldosteronism have been reported for the first time." | 2.46 | Aldosterone and cardiovascular disease. ( Carey, RM, 2010) |
| "Aliskiren has generally been well tolerated with adverse events and discontinuation rates similar to placebo in most clinical trials." | 2.46 | Inhibition of the renin angiotensin aldosterone system: focus on aliskiren. ( Rao, MS, 2010) |
| "Aldosterone is an adrenal hormone that regulates sodium, fluid, and potassium balance." | 2.45 | Aldosterone and cardiovascular disease. ( Calhoun, DA; Gaddam, KK; Husain, S; Pimenta, E, 2009) |
| "Amiloride was originally described in 1967 as a potassium-sparing diuretic, the mechanism of action of which is to block the epithelial sodium channel (ENaC) within the distal tubule of the kidney." | 2.44 | Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. ( Teiwes, J; Toto, RD, 2007) |
| "Torcetrapib was the first CETP inhibitor to enter a large-scale, prospective, placebo-controlled interventional trial, which was prematurely terminated in December 2006 because of excess cardiovascular and noncardiovascular mortality in the active treatment group." | 2.44 | Spotlight on HDL-raising therapies: insights from the torcetrapib trials. ( Chapman, MJ; Guérin, M; Kontush, A, 2008) |
| "Primary aldosteronism has been shown to represent 8-13% (rather than <1%) of unselected hypertensive patients, and patients with primary aldosteronism to have higher indices of cardiovascular damage than controls of the same age, sex, and BP status." | 2.44 | The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. ( Funder, JW, 2007) |
| "Hypertension is often associated clinically with diabetes as part of the insulin-resistance syndrome or as a manifestation of renal disease." | 2.43 | Hypertension and diabetes: role of the renin-angiotensin system. ( Cooper, ME; Jandeleit-Dahm, K, 2006) |
| "Aldosterone is a mineralocorticoid primarily produced in the zona glomerulosa of the adrenal gland." | 2.43 | Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard? ( Dostal, DE; Jewell, CW; Mock, J; Watson, LE, 2006) |
| "Thus, COPD has been called a systemic disease." | 2.43 | Neurohumoral activation as a link to systemic manifestations of chronic lung disease. ( Andreas, S; Anker, SD; Scanlon, PD; Somers, VK, 2005) |
| "Aldosterone thereby plays an important role in atherosclerosis and hypertension-induced vascular injury." | 2.43 | The mineralocorticoid receptor and oxidative stress. ( Fiebeler, A; Luft, FC, 2005) |
| "Aldosterone has recently been recognized as an important factor in the development and progression of cardiorenal disease." | 2.43 | Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial? ( Coca, SG; Perazella, MA, 2005) |
| "Aldosterone plays an important role in the pathophysiology of sodium/potassium and water homeostasis of the body." | 2.43 | Cardiovascular effects of aldosterone. ( Murin, J, 2005) |
| "Clinical experience in primary aldosteronism supports the concept that aldosterone is a risk factor of cardiovascular complications, since concentric type of cardiac hypertrophy is most common in primary aldosteronism among various types of endocrine hypertension." | 2.42 | [Aldosterone]. ( Naruse, M; Takagi, S; Takano, K; Tanabe, A; Tsuiki, M; Watanabe, D, 2004) |
| "Aldosterone has attracted considerable interest as an independent cardiovascular risk marker, which has been demonstrated in a number of studies." | 2.42 | Rapid effects of aldosterone on vascular cells: clinical implications. ( Boldyreff, B; Lösel, R; Schultz, A; Wehling, M, 2004) |
| "Aldosterone has been overlooked as a mediator of RAAS escape and a key factor in target-organ injury despite the use of available RAAS blockers." | 2.42 | RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. ( Lakkis, J; Lu, WX; Weir, MR, 2003) |
| "With the use of ACE-inhibitors in the treatment of hypertension and heart failure, less attention has been paid to aldosterone." | 2.41 | [Aldosterone and cardiovascular diseases, more than water and salt retention]. ( Duprez, D, 2002) |
| "Primary aldosteronism is the most frequent secondary hypertensive disease and is characterized by an elevated risk for cardiovascular disease." | 1.91 | Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism. ( Fujiwara, A; Haruna, A; Haze, T; Hirawa, N; Kawano, R; Kobayashi, Y; Ohki, Y; Ozawa, M; Saka, S; Suzuki, S; Tamura, K, 2023) |
| "Patients with primary aldosteronism (PA) have a higher risk of cardiovascular disease (CVD) than essential hypertension due to underlying hyperaldosteronism." | 1.91 | High plasma aldosterone concentration is associated with worse 24-h ambulatory blood pressure profile in patients with primary aldosteronism. ( Azushima, K; Haze, T; Kanaoka, T; Kinguchi, S; Kobayashi, K; Kobayashi, R; Morita, R; Sunohara, S; Tamura, K; Toya, Y; Wakui, H, 2023) |
| "In patients suffering from primary adrenal insufficiency (AI) mortality is increased despite adequate glucocorticoid (GC) and mineralocorticoid (MC) replacement therapy, mainly due to an increased cardiovascular risk." | 1.51 | Identifying a disease-specific renin-angiotensin-aldosterone system fingerprint in patients with primary adrenal insufficiency. ( Beiglböck, H; Fellinger, P; Gessl, A; Kautzky-Willer, A; Krebs, M; Luger, A; Mayr, J; Poglitsch, M; Winhofer, Y; Wolf, P, 2019) |
| "Mean aldosterone levels were highest in the TT group and lowest in CC group (p = 0." | 1.48 | Modulation of aldosterone levels by aldosterone synthase promoter polymorphism and association with eGFR decline in patients with chronic kidney disease. ( Gu, Y; Hao, C; Lai, L; Qian, J; Shi, H; Yan, M; Zhong, J, 2018) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 1.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "All primary aldosteronism patients were diagnosed by autonomous aldosterone secretion using confirmatory tests, and then divided into nPA (n = 130) and primary aldosteronism patients with high PAC (hPA: n = 162) using a PAC cutoff level of less than 443 pmol/l (16 ng/dl), representing the normal upper limit of PAC." | 1.46 | Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. ( Hamasaki, T; Hashimoto, K; Hayashi, RD; Kajimoto, Y; Kitamura, T; Kouhara, H; Kurebayashi, S; Mukai, K; Murata, M; Nakao, M; Otsuki, M; Shimomura, I; Takeiri, S; Tamada, D; Yamamoto, T, 2017) |
| "Primary aldosteronism is the most frequent endocrine cause of secondary hypertension." | 1.42 | Primary aldosteronism and its various clinical scenarios. ( Abad-Cardiel, M; Alvarez-Alvarez, B; García-Donaire, JA; Martell-Claros, N; Pérez, CF, 2015) |
| "Aldosterone is an inverse predictor of mortality and CV events in ESRD patients." | 1.42 | Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. ( Abd ElHafeez, S; Mallamaci, F; Tripepi, G; Zoccali, C, 2015) |
| "Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years." | 1.42 | Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up. ( Bailey, KR; Buglioni, A; Burnett, JC; Cannone, V; Heublein, DM; Rodeheffer, RJ; Sangaralingham, SJ; Sarzani, R; Scott, CG, 2015) |
| "Aldosterone regulation was characterized by the ratio of maximal suppression to stimulation (supine serum aldosterone on a liberal sodium diet divided by the same measure on a restricted sodium diet)." | 1.40 | Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. ( Adler, GK; Brown, JM; Ferri, C; Hopkins, PN; Underwood, PC; Vaidya, A; Williams, GH, 2014) |
| "Aldosterone was associated with congestive heart failure (adjusted hazard ratio, 1." | 1.40 | Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. ( Bansal, N; Deo, R; Feldman, HI; Keane, MG; Khan, AM; Leonard, MB; Shlipak, MG; Soliman, EZ; Steigerwalt, S; Townsend, RR; Yang, W; Zhang, X, 2014) |
| "Primary aldosteronism (PA), the most frequent form of secondary hypertension, is characterized by a higher rate of cardiovascular (CV) events than essential hypertension (EH)." | 1.40 | Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment. ( Boscaro, M; Ceccoli, L; di Tizio, V; Giacchetti, G; Ronconi, V; Turchi, F, 2014) |
| "Primary hyperaldosteronism is the most common cause of secondary hypertension." | 1.39 | Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk. ( Abad-Cardiel, M; Alvarez-Álvarez, B; Fernández, C; Fernández-Cruz, A; Luque-Fernandez, L; Martell-Claros, N, 2013) |
| "CVD mortality and sudden cardiac death events at 7." | 1.37 | Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. ( Boehm, BO; Drechsler, C; Grammer, T; März, W; Pilz, S; Ritz, E; Tomaschitz, A, 2011) |
| "The evidence is compelling for a role of inflammation in cardiovascular diseases; however, the chronic use of anti-inflammatory drugs for these indications has been disappointing." | 1.35 | Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. ( Aiyar, N; Behm, DJ; Bentley, RG; Coatney, RW; Doe, CP; Eybye, ME; Maniscalco, K; Olzinski, AR; Westfall, TD; Willette, RN; Zhao, S, 2009) |
| "Primary hyperparathyroidism is associated with an increased cardiovascular morbidity and mortality." | 1.35 | Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. ( Alrasheedi, S; Ayav, A; Bresler, L; Brunaud, L; Caillard, C; Germain, A; Mirallie, E; Rancier, M; Weryha, G; Zarnegar, R, 2009) |
| "Patients with primary aldosteronism were compared with patients with essential hypertension and were treated to reach a blood pressure of less than 140/90 mm Hg." | 1.35 | Cardiovascular outcomes in patients with primary aldosteronism after treatment. ( Baroselli, S; Catena, C; Chiuch, A; Colussi, G; Lapenna, R; Nadalini, E; Sechi, LA, 2008) |
| "Aldosterone levels were significantly increased (P < 0." | 1.33 | Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. ( Cascella, T; Colao, A; Di Biase, S; Giallauria, F; Labella, D; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Tauchmanovà, L; Vigorito, C, 2006) |
| "Spironolactone treatment decreased PAI-1 immunoreactivity and reduced in a dose-dependent fashion cardiac and renal damage." | 1.32 | Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. ( Adler, GK; Jonasson, L; Martinez-Vasquez, D; Mukasa, K; Oestreicher, EM; Roubsanthisuk, W; Stone, JR, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (6.92) | 18.7374 |
| 1990's | 7 (2.42) | 18.2507 |
| 2000's | 99 (34.26) | 29.6817 |
| 2010's | 131 (45.33) | 24.3611 |
| 2020's | 32 (11.07) | 2.80 |
| Authors | Studies |
|---|---|
| Kolkhof, P | 1 |
| Joseph, A | 1 |
| Kintscher, U | 1 |
| Ready, JM | 1 |
| Bauersachs, J | 2 |
| López-Andrés, N | 1 |
| Parksook, WW | 1 |
| Williams, GH | 7 |
| Nomura, M | 1 |
| Kurihara, I | 3 |
| Itoh, H | 3 |
| Ichijo, T | 4 |
| Katabami, T | 3 |
| Tsuiki, M | 5 |
| Wada, N | 4 |
| Yoneda, T | 4 |
| Sone, M | 3 |
| Oki, K | 4 |
| Yamada, T | 1 |
| Kobayashi, H | 5 |
| Tamura, K | 5 |
| Ogawa, Y | 2 |
| Inagaki, N | 4 |
| Yamamoto, K | 3 |
| Otsuki, M | 3 |
| Yabe, D | 1 |
| Izawa, S | 4 |
| Takahashi, Y | 1 |
| Suzuki, T | 2 |
| Yasoda, A | 1 |
| Tanabe, A | 4 |
| Naruse, M | 5 |
| Morimoto, S | 1 |
| Ichihara, A | 1 |
| Rossi, GP | 3 |
| Rossitto, G | 1 |
| Wu, VC | 2 |
| Peng, KY | 1 |
| Hu, YH | 1 |
| Chang, CC | 1 |
| Chan, CK | 1 |
| Lai, TS | 1 |
| Lin, YH | 2 |
| Wang, SM | 1 |
| Lu, CC | 1 |
| Liu, YC | 1 |
| Tsai, YC | 1 |
| Chueh, JS | 1 |
| Gan, L | 1 |
| Li, N | 1 |
| Heizhati, M | 1 |
| Lin, M | 1 |
| Zhu, Q | 1 |
| Yao, X | 1 |
| Wu, T | 1 |
| Wang, M | 1 |
| Luo, Q | 1 |
| Zhang, D | 1 |
| Jiang, W | 1 |
| Hu, J | 1 |
| Haze, T | 3 |
| Ozawa, M | 1 |
| Kawano, R | 1 |
| Haruna, A | 1 |
| Ohki, Y | 1 |
| Suzuki, S | 1 |
| Kobayashi, Y | 1 |
| Fujiwara, A | 1 |
| Saka, S | 1 |
| Hirawa, N | 2 |
| Renke, G | 1 |
| Starling-Soares, B | 1 |
| Baesso, T | 1 |
| Petronio, R | 1 |
| Aguiar, D | 1 |
| Paes, R | 1 |
| Alexander, BT | 1 |
| South, AM | 1 |
| August, P | 1 |
| Bertagnolli, M | 1 |
| Ferranti, EP | 1 |
| Grobe, JL | 1 |
| Jones, EJ | 1 |
| Loria, AS | 1 |
| Safdar, B | 1 |
| Sequeira-Lopez, MLS | 1 |
| Otsuka, H | 1 |
| Abe, M | 1 |
| Yuan, YE | 1 |
| Haas, AV | 1 |
| Taylor, H | 1 |
| Seely, EW | 1 |
| Adler, GK | 9 |
| An, J | 1 |
| Zhou, H | 1 |
| Ni, L | 1 |
| Harrision, TN | 1 |
| Wei, R | 1 |
| Agiro, A | 1 |
| Brahmbhatt, YG | 1 |
| Oluwatosin, Y | 1 |
| Schilling, CG | 1 |
| Sim, JJ | 2 |
| Morita, R | 1 |
| Azushima, K | 1 |
| Sunohara, S | 1 |
| Kobayashi, R | 1 |
| Kinguchi, S | 1 |
| Kanaoka, T | 1 |
| Kobayashi, K | 1 |
| Toya, Y | 1 |
| Wakui, H | 1 |
| Wang, C | 1 |
| Cui, Y | 1 |
| Zhu, Y | 1 |
| Wang, F | 1 |
| Rong, Q | 1 |
| Zhang, Y | 1 |
| Chen, ZW | 1 |
| Tsai, CH | 1 |
| Pan, CT | 1 |
| Chou, CH | 1 |
| Liao, CW | 1 |
| Hung, CS | 1 |
| Mayyas, FA | 1 |
| Aljohmani, AI | 1 |
| Alzoubi, KH | 1 |
| Kumar, A | 1 |
| Patel, DR | 1 |
| Brennan, DM | 1 |
| Wolski, KE | 1 |
| Lincoff, AM | 1 |
| Ruotolo, G | 1 |
| McErlean, E | 1 |
| Weerakkody, G | 1 |
| Riesmeyer, JS | 1 |
| Nicholls, SJ | 2 |
| Nissen, SE | 1 |
| Menon, V | 1 |
| Xiao, Z | 1 |
| King, G | 1 |
| Mancarella, S | 1 |
| Munkhsaikhan, U | 1 |
| Cao, L | 1 |
| Cai, C | 1 |
| Quarles, LD | 1 |
| Seccia, TM | 1 |
| Maiolino, G | 1 |
| Cesari, M | 1 |
| Adolf, C | 1 |
| Schneider, H | 1 |
| Heinrich, DA | 1 |
| Handgriff, L | 1 |
| Reincke, M | 3 |
| Agarwal, A | 1 |
| Cheung, AK | 1 |
| Gao, X | 1 |
| Yamazaki, Y | 1 |
| Tezuka, Y | 1 |
| Omata, K | 1 |
| Ono, Y | 1 |
| Morimoto, R | 1 |
| Nakamura, Y | 1 |
| Satoh, F | 1 |
| Sasano, H | 1 |
| Grübler, MR | 1 |
| Delgado, G | 1 |
| Kleber, M | 1 |
| Hartaigh, BÓ | 2 |
| de Boer, RA | 3 |
| Verheyen, N | 2 |
| Keppel, M | 1 |
| Schmid, J | 1 |
| Siontis, GC | 1 |
| Räber, L | 1 |
| Pieske, B | 4 |
| Pilz, S | 9 |
| Tomaschitz, A | 10 |
| März, W | 10 |
| Young, MJ | 5 |
| Kanki, M | 1 |
| Fuller, PJ | 4 |
| Yang, J | 1 |
| Wang, L | 1 |
| Zhang, Z | 2 |
| Liu, D | 1 |
| Yuan, K | 1 |
| Zhu, G | 1 |
| Qi, X | 1 |
| Srinivasa, S | 1 |
| Thomas, TS | 1 |
| Feldpausch, MN | 1 |
| Grinspoon, SK | 1 |
| Yano, Y | 1 |
| Okamura, S | 2 |
| Kai, T | 1 |
| Yamada, M | 1 |
| Chiba, Y | 1 |
| Epstein, M | 5 |
| Okamoto, K | 1 |
| Ohno, Y | 2 |
| Takeda, Y | 4 |
| Demura, M | 1 |
| Gafane-Matemane, LF | 1 |
| Kruger, R | 1 |
| Smith, W | 1 |
| Mels, CMC | 1 |
| Van Rooyen, JM | 1 |
| Mokwatsi, GG | 1 |
| Uys, AS | 1 |
| Brits, SJ | 1 |
| Schutte, AE | 1 |
| Mandal, R | 1 |
| Kaur, S | 1 |
| Gupta, VK | 1 |
| Joshi, A | 1 |
| Zelzer, S | 1 |
| Enko, D | 1 |
| Meinitzer, A | 3 |
| Hao, Z | 1 |
| Li, G | 1 |
| Sun, Y | 1 |
| Liu, Y | 1 |
| Ferrario, CM | 2 |
| Mullick, AE | 1 |
| Donderski, R | 1 |
| Stróżecki, P | 1 |
| Sulikowska, B | 1 |
| Grajewska, M | 1 |
| Miśkowiec, I | 1 |
| Stefańska, A | 1 |
| Siódmiak, J | 1 |
| Odrowąż-Sypniewska, G | 1 |
| Manitius, J | 1 |
| Balakumar, P | 1 |
| Anand-Srivastava, MB | 1 |
| Jagadeesh, G | 1 |
| Joseph, JJ | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Kalyani, RR | 1 |
| Yeh, HC | 1 |
| Bertoni, AG | 1 |
| Effoe, VS | 1 |
| Casanova, R | 1 |
| Sims, M | 1 |
| Wu, WC | 1 |
| Wand, GS | 1 |
| Correa, A | 1 |
| Golden, SH | 1 |
| Jia, G | 2 |
| Aroor, AR | 2 |
| Sowers, JR | 6 |
| Michael, OS | 1 |
| Olatunji, LA | 2 |
| Homma, T | 2 |
| Homma, M | 1 |
| Huang, Y | 2 |
| Mayurasakorn, K | 1 |
| Rodi, NM | 1 |
| Hamid, AAA | 1 |
| Hurwitz, S | 1 |
| Yao, T | 1 |
| Pojoga, LH | 3 |
| Romero, JR | 3 |
| Genovesi, S | 1 |
| Antolini, L | 1 |
| Orlando, A | 1 |
| Tassistro, E | 1 |
| Giussani, M | 1 |
| Nava, E | 1 |
| Turolo, L | 1 |
| Manolopoulou, J | 1 |
| Parati, G | 1 |
| Morganti, A | 1 |
| Funder, JW | 7 |
| Faulkner, JL | 1 |
| Bruder-Nascimento, T | 1 |
| Belin de Chantemèle, EJ | 3 |
| Yamasaki, T | 1 |
| Ogawa, O | 1 |
| Umakoshi, H | 1 |
| Tanaka, Y | 1 |
| Shibayama, Y | 1 |
| Yoshimoto, T | 2 |
| Kawashima, J | 1 |
| Takahashi, K | 1 |
| Fujita, M | 1 |
| Watanabe, M | 3 |
| Matsuda, Y | 1 |
| Shibata, H | 2 |
| Kamemura, K | 1 |
| Fujii, Y | 1 |
| Ogo, A | 1 |
| Miyauchi, S | 1 |
| Fukuoka, T | 1 |
| Hashimoto, S | 1 |
| Yanase, T | 1 |
| Kawamura, T | 1 |
| Tabara, Y | 1 |
| Matsuda, F | 1 |
| Armanini, D | 3 |
| Sabbadin, C | 2 |
| Donà, G | 2 |
| Bordin, L | 2 |
| Marin, L | 1 |
| Andrisani, A | 2 |
| Ambrosini, G | 2 |
| Kolodziejczyk, P | 1 |
| Gromotowicz-Poplawska, A | 1 |
| Aleksiejczuk, M | 1 |
| Chabielska, E | 1 |
| Tutka, P | 1 |
| Miltyk, W | 1 |
| Buffolo, F | 1 |
| Monticone, S | 1 |
| Tetti, M | 1 |
| Mulatero, P | 2 |
| Pezzani, R | 1 |
| Davel, AP | 1 |
| Jaffe, IZ | 3 |
| Tostes, RC | 1 |
| Jaisser, F | 3 |
| Hill, MA | 1 |
| Itcho, K | 1 |
| Kobuke, K | 1 |
| Ohno, H | 1 |
| Yoneda, M | 1 |
| Hattori, N | 1 |
| Gorini, S | 1 |
| Marzolla, V | 1 |
| Mammi, C | 1 |
| Armani, A | 1 |
| Caprio, M | 1 |
| Bazzell, BG | 1 |
| Rainey, WE | 2 |
| Auchus, RJ | 1 |
| Zocco, D | 1 |
| Bruttini, M | 1 |
| Hummel, SL | 1 |
| Byrd, JB | 1 |
| Ting, PY | 1 |
| Yao, TM | 1 |
| Brooks, D | 1 |
| Katayama Rangel, I | 1 |
| Williams, JS | 3 |
| Charytan, DM | 1 |
| Himmelfarb, J | 1 |
| Ikizler, TA | 1 |
| Raj, DS | 1 |
| Hsu, JY | 1 |
| Landis, JR | 1 |
| Anderson, AH | 1 |
| Hung, AM | 1 |
| Mehrotra, R | 1 |
| Sharma, S | 1 |
| Weiner, DE | 1 |
| Williams, M | 1 |
| DiCarli, M | 1 |
| Skali, H | 1 |
| Kimmel, PL | 1 |
| Kliger, AS | 1 |
| Dember, LM | 1 |
| Lytvyn, Y | 1 |
| Godoy, LC | 1 |
| Scholtes, RA | 1 |
| van Raalte, DH | 1 |
| Cherney, DZ | 1 |
| Qian, J | 1 |
| Zhong, J | 1 |
| Yan, M | 1 |
| Shi, H | 1 |
| Hao, C | 1 |
| Gu, Y | 1 |
| Lai, L | 1 |
| Pantelidis, P | 1 |
| Sideris, M | 1 |
| Viigimaa, M | 1 |
| Avranas, K | 1 |
| Deligkaris, P | 1 |
| Zografou, I | 1 |
| Lovic, D | 1 |
| Adlin, EV | 1 |
| Sztechman, D | 1 |
| Czarzasta, K | 1 |
| Cudnoch-Jedrzejewska, A | 1 |
| Szczepanska-Sadowska, E | 1 |
| Zera, T | 1 |
| Wolf, P | 1 |
| Mayr, J | 1 |
| Beiglböck, H | 1 |
| Fellinger, P | 1 |
| Winhofer, Y | 1 |
| Poglitsch, M | 1 |
| Gessl, A | 1 |
| Kautzky-Willer, A | 1 |
| Luger, A | 1 |
| Krebs, M | 1 |
| Matarese, G | 1 |
| Norata, GD | 1 |
| Ocello, A | 1 |
| La Rosa, S | 1 |
| Fiorini, F | 1 |
| Randone, S | 1 |
| Maccarrone, R | 1 |
| Battaglia, G | 1 |
| Granata, A | 1 |
| Tzamou, V | 1 |
| Vyssoulis, G | 1 |
| Karpanou, E | 1 |
| Kyvelou, SM | 1 |
| Gialernios, T | 1 |
| Stefanadis, C | 1 |
| He, FJ | 1 |
| Li, J | 1 |
| Macgregor, GA | 1 |
| McCurley, A | 2 |
| McGraw, A | 1 |
| Pruthi, D | 1 |
| Lambers Heerspink, HJ | 1 |
| McGraw, AP | 1 |
| Preston, IR | 1 |
| Catena, C | 2 |
| Colussi, G | 2 |
| Sechi, LA | 2 |
| Rugale, C | 1 |
| Du Cailar, G | 1 |
| Fesler, P | 1 |
| Ribstein, J | 1 |
| Mourad, G | 1 |
| Mimran, A | 1 |
| Ritz, E | 7 |
| Rus-Machan, J | 2 |
| Kienreich, K | 2 |
| Gaksch, M | 1 |
| Grübler, M | 2 |
| Fahrleitner-Pammer, A | 3 |
| Mrak, P | 1 |
| Toplak, H | 2 |
| Kraigher-Krainer, E | 2 |
| Stowasser, M | 2 |
| Mihailidou, AS | 1 |
| Baudrand, R | 1 |
| Engeli, S | 1 |
| Hu, Q | 1 |
| Yin, L | 1 |
| Hartmann, RW | 1 |
| Turchi, F | 2 |
| Ronconi, V | 3 |
| di Tizio, V | 2 |
| Ceccoli, L | 1 |
| Boscaro, M | 3 |
| Giacchetti, G | 2 |
| Brown, JM | 3 |
| Underwood, PC | 1 |
| Ferri, C | 1 |
| Hopkins, PN | 1 |
| Vaidya, A | 3 |
| Fagyas, M | 1 |
| Úri, K | 1 |
| Siket, IM | 1 |
| Daragó, A | 1 |
| Boczán, J | 1 |
| Bányai, E | 1 |
| Édes, I | 1 |
| Papp, Z | 1 |
| Tóth, A | 1 |
| Deo, R | 1 |
| Yang, W | 1 |
| Khan, AM | 1 |
| Bansal, N | 1 |
| Zhang, X | 1 |
| Leonard, MB | 1 |
| Keane, MG | 1 |
| Soliman, EZ | 1 |
| Steigerwalt, S | 1 |
| Townsend, RR | 1 |
| Shlipak, MG | 1 |
| Feldman, HI | 1 |
| Ikeda, K | 1 |
| Chrissobolis, S | 2 |
| Drummond, GR | 1 |
| Faraci, FM | 1 |
| Sobey, CG | 1 |
| Bakris, GL | 1 |
| Lother, A | 1 |
| Moser, M | 1 |
| Bode, C | 1 |
| Feldman, RD | 3 |
| Hein, L | 1 |
| Kitamoto, T | 1 |
| Suematsu, S | 1 |
| Matsuzawa, Y | 1 |
| Saito, J | 1 |
| Omura, M | 1 |
| Nishikawa, T | 1 |
| Lang, F | 1 |
| Alesutan, I | 1 |
| Voelkl, J | 1 |
| Feliciano Pereira, P | 1 |
| Eloiza Priore, S | 1 |
| Bressan, J | 1 |
| Lieb, W | 2 |
| Chen, MH | 2 |
| Teumer, A | 1 |
| Lin, H | 2 |
| Fox, ER | 2 |
| Musani, SK | 2 |
| Wilson, JG | 1 |
| Wang, TJ | 3 |
| Völzke, H | 1 |
| Petersen, AK | 1 |
| Meisinger, C | 1 |
| Nauck, M | 1 |
| Schlesinger, S | 1 |
| Li, Y | 1 |
| Menard, J | 1 |
| Hercberg, S | 1 |
| Wichmann, HE | 1 |
| Völker, U | 1 |
| Rawal, R | 1 |
| Bidlingmaier, M | 1 |
| Hannemann, A | 1 |
| Dörr, M | 1 |
| Rettig, R | 1 |
| van Gilst, WH | 2 |
| van Veldhuisen, DJ | 2 |
| Bakker, SJ | 3 |
| Navis, G | 3 |
| Wallaschofski, H | 1 |
| Meneton, P | 1 |
| van der Harst, P | 2 |
| Vasan, RS | 4 |
| Schiffrin, EL | 3 |
| Kraja, A | 1 |
| Bidulescu, A | 1 |
| Beecham, A | 1 |
| Felix, JF | 1 |
| Fox, CS | 2 |
| Kao, WH | 1 |
| Kardia, SL | 1 |
| Liu, CT | 1 |
| Nalls, MA | 1 |
| Rundek, T | 1 |
| Sacco, RL | 1 |
| Smith, J | 1 |
| Sun, YV | 1 |
| Wilson, G | 1 |
| Mosley, TH | 1 |
| Taylor, HA | 1 |
| Cornelius, RJ | 1 |
| Wen, D | 1 |
| Li, H | 1 |
| Yuan, Y | 1 |
| Wang-France, J | 1 |
| Warner, PC | 1 |
| Sansom, SC | 1 |
| Fortunato, A | 1 |
| Prontera, C | 1 |
| Masotti, S | 1 |
| Franzini, M | 1 |
| Marchetti, C | 1 |
| Giovannini, S | 1 |
| Zucchelli, GC | 1 |
| Emdin, M | 1 |
| Passino, C | 1 |
| Clerico, A | 1 |
| Martell-Claros, N | 2 |
| Abad-Cardiel, M | 2 |
| Alvarez-Alvarez, B | 2 |
| García-Donaire, JA | 1 |
| Pérez, CF | 1 |
| Ueda, T | 1 |
| Kawakami, R | 1 |
| Nishida, T | 1 |
| Onoue, K | 1 |
| Soeda, T | 1 |
| Okayama, S | 1 |
| Kawata, H | 1 |
| Uemura, S | 1 |
| Saito, Y | 1 |
| Brandenburg, VM | 1 |
| Scharnagl, H | 1 |
| Kapl, M | 1 |
| Grammer, T | 2 |
| Horina, JH | 2 |
| Kleber, ME | 2 |
| van Ballegooijen, AJ | 1 |
| Amrein, K | 1 |
| Garg, R | 1 |
| Abd ElHafeez, S | 1 |
| Tripepi, G | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 1 |
| Takeuchi, D | 1 |
| Furutani, M | 1 |
| Harada, Y | 1 |
| Furutani, Y | 1 |
| Inai, K | 1 |
| Nakanishi, T | 1 |
| Matsuoka, R | 1 |
| Lyngsø, KS | 1 |
| Assersen, K | 1 |
| Dalgaard, EG | 1 |
| Skott, O | 1 |
| Jensen, BL | 3 |
| Hansen, PB | 3 |
| Farman, N | 2 |
| Buglioni, A | 1 |
| Cannone, V | 1 |
| Sangaralingham, SJ | 1 |
| Heublein, DM | 1 |
| Scott, CG | 1 |
| Bailey, KR | 1 |
| Rodeheffer, RJ | 1 |
| Sarzani, R | 1 |
| Burnett, JC | 1 |
| Usman, TO | 1 |
| Seok, YM | 1 |
| Kim, IK | 1 |
| Huby, AC | 1 |
| Otvos, L | 1 |
| Bruno, RM | 2 |
| Taddei, S | 2 |
| Tan, HK | 1 |
| James, PD | 1 |
| Wong, F | 1 |
| Kitajima, N | 1 |
| Seki, T | 2 |
| Yasuda, A | 1 |
| Oki, M | 1 |
| Takagi, A | 1 |
| Hanai, K | 1 |
| Terachi, T | 1 |
| Fukagawa, M | 1 |
| Elbers, LP | 1 |
| Sjouke, B | 1 |
| Zannad, F | 2 |
| Cicoira, M | 1 |
| Vizzardi, E | 1 |
| Václavík, J | 1 |
| Gerdes, VE | 1 |
| Squizzato, A | 1 |
| Delgado, GE | 1 |
| Siekmeier, R | 1 |
| Krämer, BK | 1 |
| Carrara, D | 1 |
| Bacca, A | 1 |
| Duranti, E | 1 |
| Ghiadoni, L | 1 |
| Bernini, G | 1 |
| Limbird, LE | 1 |
| Mascolo, A | 1 |
| Sessa, M | 1 |
| Scavone, C | 1 |
| De Angelis, A | 1 |
| Vitale, C | 1 |
| Berrino, L | 1 |
| Rossi, F | 1 |
| Rosano, G | 1 |
| Capuano, A | 1 |
| Pitts, R | 1 |
| Gunzburger, E | 1 |
| Ballantyne, CM | 1 |
| Barter, PJ | 1 |
| Kallend, D | 1 |
| Leiter, LA | 1 |
| Leitersdorf, E | 1 |
| Shah, PK | 1 |
| Tardif, JC | 1 |
| Olsson, AG | 1 |
| McMurray, JJ | 1 |
| Kittelson, J | 1 |
| Schwartz, GG | 1 |
| Murata, M | 1 |
| Kitamura, T | 1 |
| Tamada, D | 1 |
| Mukai, K | 1 |
| Kurebayashi, S | 1 |
| Yamamoto, T | 1 |
| Hashimoto, K | 1 |
| Hayashi, RD | 1 |
| Kouhara, H | 1 |
| Takeiri, S | 1 |
| Kajimoto, Y | 1 |
| Nakao, M | 1 |
| Hamasaki, T | 1 |
| Shimomura, I | 1 |
| Joy, TR | 1 |
| Hegele, RA | 1 |
| Ruilope, LM | 1 |
| Lastra-Gonzalez, G | 2 |
| Manrique-Acevedo, C | 2 |
| Geft, D | 1 |
| Schwartzenberg, S | 1 |
| George, J | 1 |
| Rahimtoola, SH | 1 |
| Gaddam, KK | 1 |
| Pimenta, E | 2 |
| Husain, S | 1 |
| Calhoun, DA | 2 |
| Lastra-Lastra, G | 1 |
| Restrepo-Erazo, K | 1 |
| Klemmer, PJ | 1 |
| Bomback, AS | 2 |
| Kidambi, S | 1 |
| Kotchen, JM | 1 |
| Krishnaswami, S | 1 |
| Grim, CE | 1 |
| Kotchen, TA | 2 |
| Aplin, M | 1 |
| Christensen, GL | 1 |
| Hansen, JL | 1 |
| Joseph, J | 1 |
| Pencina, MJ | 2 |
| Hayes, L | 1 |
| Tofler, GH | 2 |
| Jacques, P | 1 |
| Selhub, J | 2 |
| Levy, D | 2 |
| D'Agostino, RB | 2 |
| Benjamin, EJ | 2 |
| Yanes, LL | 1 |
| Romero, DG | 1 |
| Hayashi, T | 1 |
| Takai, S | 1 |
| Yamashita, C | 1 |
| Whaley-Connell, A | 1 |
| Willette, RN | 1 |
| Eybye, ME | 1 |
| Olzinski, AR | 1 |
| Behm, DJ | 1 |
| Aiyar, N | 1 |
| Maniscalco, K | 1 |
| Bentley, RG | 1 |
| Coatney, RW | 1 |
| Zhao, S | 1 |
| Westfall, TD | 1 |
| Doe, CP | 1 |
| Gomez Sanchez, EP | 1 |
| Little, WC | 1 |
| Kirkman, PM | 1 |
| Toto, R | 1 |
| Vogt, B | 1 |
| Burnier, M | 1 |
| Brunaud, L | 1 |
| Germain, A | 1 |
| Zarnegar, R | 1 |
| Rancier, M | 1 |
| Alrasheedi, S | 1 |
| Caillard, C | 1 |
| Ayav, A | 1 |
| Weryha, G | 1 |
| Mirallie, E | 1 |
| Bresler, L | 1 |
| Boehm, BO | 2 |
| Briet, M | 2 |
| Gros, R | 1 |
| Vinson, GP | 1 |
| Coghlan, JP | 1 |
| Carey, RM | 1 |
| Boschitsch, E | 1 |
| Mayerhofer, S | 1 |
| Magometschnigg, D | 1 |
| Toto, RD | 2 |
| Rao, MS | 1 |
| Usher, MG | 1 |
| Duan, SZ | 1 |
| Ivaschenko, CY | 1 |
| Frieler, RA | 1 |
| Berger, S | 1 |
| Schütz, G | 1 |
| Lumeng, CN | 1 |
| Mortensen, RM | 1 |
| Lastra, G | 1 |
| Dhuper, S | 1 |
| Johnson, MS | 1 |
| Cavalier, E | 1 |
| Maksimov, ML | 1 |
| Alvarez-Madrazo, S | 1 |
| Connell, JM | 2 |
| Freel, EM | 1 |
| Drechsler, C | 2 |
| Dooley, R | 1 |
| Harvey, BJ | 1 |
| Thomas, W | 1 |
| Gomez-Sanchez, EP | 2 |
| Waanders, F | 1 |
| de Vries, LV | 1 |
| van Goor, H | 2 |
| Hillebrands, JL | 1 |
| Laverman, GD | 1 |
| Shi, J | 1 |
| Calara, F | 1 |
| Rasgon, S | 1 |
| Jacobsen, S | 1 |
| Kalantar-Zadeh, K | 1 |
| Appolloni, G | 1 |
| Gustafsson, F | 1 |
| Azizi, M | 1 |
| Rossignol, P | 1 |
| Kim-Mitsuyama, S | 1 |
| Horký, K | 1 |
| Ofner, M | 1 |
| Pieber, TR | 1 |
| Queisser, N | 1 |
| Schupp, N | 1 |
| Alderman, MH | 1 |
| Cohen, HW | 1 |
| Gordon, RD | 1 |
| Schroten, NF | 1 |
| Mahmud, H | 1 |
| Szymanski, MK | 1 |
| Gansevoort, RT | 1 |
| Hillege, HL | 1 |
| Hawkins, UA | 1 |
| Gomez-Sanchez, CM | 1 |
| Gomez-Sanchez, CE | 1 |
| Krum, H | 2 |
| He, BJ | 1 |
| Anderson, ME | 1 |
| Patel, BM | 1 |
| Mehta, AA | 1 |
| dos Santos, PP | 1 |
| Nogueira, BF | 1 |
| Rafacho, BP | 1 |
| Azevedo, PS | 1 |
| Polegato, BF | 1 |
| Chiuso-Minicucci, F | 1 |
| Bonomo, C | 1 |
| Roscani, MG | 1 |
| Zorzella-Pezavento, SF | 1 |
| Tanni, SE | 1 |
| Pereira, EJ | 1 |
| Okoshi, MP | 1 |
| Paiva, SA | 1 |
| Zornoff, LA | 1 |
| Minicucci, MF | 1 |
| Al-Salameh, A | 1 |
| Cohen, R | 1 |
| Chanson, P | 1 |
| Plouin, PF | 1 |
| Kisaka, T | 1 |
| Ozono, R | 1 |
| Ishida, T | 1 |
| Higashi, Y | 1 |
| Oshima, T | 1 |
| Kihara, Y | 1 |
| Luque-Fernandez, L | 1 |
| Fernández, C | 1 |
| Fernández-Cruz, A | 1 |
| Nishimoto, K | 1 |
| Bollag, WB | 1 |
| Duprez, D | 1 |
| Rocha, R | 3 |
| Weber, MA | 1 |
| Liew, D | 1 |
| Buikema, H | 1 |
| Bravo, EL | 1 |
| Lösel, R | 2 |
| Feuring, M | 2 |
| Wehling, M | 3 |
| Brown, NJ | 5 |
| Lakkis, J | 1 |
| Lu, WX | 1 |
| Weir, MR | 1 |
| KODEJSZKO, E | 1 |
| KOLINSKA, M | 1 |
| KUCZEWSKA, K | 1 |
| TATON, J | 1 |
| LAMBREW, CT | 1 |
| CARVER, ST | 1 |
| PETERSON, RE | 1 |
| HORWITH, M | 1 |
| HARTROFT, WS | 1 |
| HARTROFT, PM | 1 |
| YOSHITOSHI, Y | 1 |
| MASUYAMA, Y | 1 |
| POLIANTSEVA, LR | 1 |
| ERMOLENKO, VM | 1 |
| Oestreicher, EM | 1 |
| Martinez-Vasquez, D | 1 |
| Stone, JR | 1 |
| Jonasson, L | 1 |
| Roubsanthisuk, W | 1 |
| Mukasa, K | 1 |
| Struthers, AD | 2 |
| MacDonald, TM | 1 |
| Christ, M | 1 |
| Grimm, W | 1 |
| Maisch, B | 1 |
| Black, HR | 1 |
| Garthwaite, SM | 1 |
| McMahon, EG | 1 |
| Miyamori, I | 2 |
| Uhrenholt, TR | 2 |
| Schjerning, J | 2 |
| Rasmussen, LE | 2 |
| Nørregaard, R | 1 |
| Skøtt, O | 2 |
| Schultz, A | 1 |
| Boldyreff, B | 1 |
| Watanabe, D | 1 |
| Takagi, S | 1 |
| Takano, K | 1 |
| Yasue, H | 1 |
| Mizuno, Y | 1 |
| Harada, E | 1 |
| Ito, T | 1 |
| Ambroisine, ML | 1 |
| Milliez, P | 1 |
| Nehme, J | 1 |
| Pasquier, AL | 1 |
| De Angelis, N | 1 |
| Mansier, P | 1 |
| Swynghedauw, B | 1 |
| Delcayre, C | 1 |
| Vintilă, M | 1 |
| Băluţă, M | 1 |
| Rossi, G | 1 |
| Murin, J | 1 |
| Coca, SG | 1 |
| Perazella, MA | 1 |
| Joffe, HV | 1 |
| Fiebeler, A | 2 |
| Luft, FC | 2 |
| Stier, CT | 2 |
| Chander, PN | 1 |
| Radauceanu, A | 1 |
| Krysiak, R | 1 |
| Okopień, B | 1 |
| Herman, ZS | 1 |
| Calò, LA | 1 |
| Andreas, S | 1 |
| Anker, SD | 1 |
| Scanlon, PD | 1 |
| Somers, VK | 1 |
| Goodfriend, TL | 1 |
| Kalantarinia, K | 1 |
| Okusa, MD | 1 |
| Milan, A | 1 |
| Williams, TA | 1 |
| Veglio, F | 1 |
| Jewell, CW | 1 |
| Watson, LE | 1 |
| Mock, J | 1 |
| Dostal, DE | 1 |
| Knights, KM | 1 |
| Mangoni, AA | 1 |
| Miners, JO | 1 |
| Kawai, Y | 1 |
| Fan, CY | 1 |
| Hirata, Y | 3 |
| Cascella, T | 1 |
| Palomba, S | 1 |
| Tauchmanovà, L | 1 |
| Manguso, F | 1 |
| Di Biase, S | 1 |
| Labella, D | 1 |
| Giallauria, F | 1 |
| Vigorito, C | 1 |
| Colao, A | 1 |
| Lombardi, G | 1 |
| Orio, F | 1 |
| Jandeleit-Dahm, K | 1 |
| Cooper, ME | 2 |
| Teiwes, J | 1 |
| Hayashi, K | 1 |
| Wakino, S | 1 |
| Sugano, N | 1 |
| Ozawa, Y | 1 |
| Homma, K | 1 |
| Saruta, T | 1 |
| Hamming, I | 1 |
| Haagmans, BL | 1 |
| Hooper, NM | 1 |
| Korstanje, R | 1 |
| Osterhaus, AD | 1 |
| Timens, W | 1 |
| Turner, AJ | 1 |
| Marney, AM | 1 |
| Ingelsson, E | 1 |
| Lanier, KJ | 1 |
| Jacques, PF | 1 |
| Meigs, JB | 1 |
| Larson, MG | 1 |
| Okamoto, H | 1 |
| Matsumura, Y | 1 |
| Nishiyama, A | 1 |
| Kusaka, T | 1 |
| Kitajima, H | 1 |
| Nagata, D | 1 |
| Nadalini, E | 1 |
| Chiuch, A | 1 |
| Baroselli, S | 1 |
| Lapenna, R | 1 |
| Krug, AW | 1 |
| Ehrhart-Bornstein, M | 1 |
| Kontush, A | 1 |
| Guérin, M | 1 |
| Chapman, MJ | 1 |
| Dullaart, RP | 1 |
| Kobold, AC | 1 |
| van Tol, A | 1 |
| Atlas, SA | 1 |
| Case, DB | 1 |
| Halberg, F | 1 |
| Stasiński, T | 1 |
| Lehmann, Z | 1 |
| Kostka-Wach, M | 1 |
| Biryńczyk, J | 1 |
| Warenik-Szymankiewicz, A | 1 |
| Laragh, JH | 1 |
| Grunenberger, F | 1 |
| Soubrier, F | 1 |
| Lajemi, M | 1 |
| Gautier, S | 1 |
| Benetos, A | 1 |
| Reyes, AJ | 1 |
| Taylor, SH | 1 |
| Delyani, JA | 1 |
| Lombès, M | 1 |
| Bonvalet, JP | 1 |
| Zennaro, MC | 1 |
| Weber, KT | 1 |
| Pasquale, PD | 1 |
| Stefano, GD | 1 |
| Paterna, S | 1 |
| Schmidt, F | 1 |
| Müller, DN | 1 |
| Park, JK | 1 |
| Dechend, R | 1 |
| Bieringer, M | 1 |
| Shagdarsuren, E | 1 |
| Breu, V | 1 |
| Haller, H | 1 |
| Abbas, A | 1 |
| Byrne, D | 1 |
| Schoenhard, JA | 1 |
| Vaughan, DE | 1 |
| Cavallin, M | 1 |
| Nussdorfer, GG | 1 |
| Pessina, AC | 1 |
| Melby, JC | 1 |
| Weinberg, MS | 1 |
| Weinberg, AJ | 1 |
| Zappe, DH | 1 |
| Garagezova, AR | 1 |
| Lösel, RM | 1 |
| Falkenstein, E | 1 |
| Padmanabhan, N | 1 |
| Padmanabhan, S | 1 |
| Ivkov, VG | 1 |
| Sidorenko, BA | 1 |
| Kudisov, IuM | 1 |
| Rossel's, AN | 1 |
| Razumova, ET | 1 |
| Nosova, NP | 1 |
| Kazanova, LR | 1 |
| Ubrantsev, VA | 1 |
| Iams, SG | 1 |
| Wexler, BC | 1 |
| Vertes, V | 1 |
| Kannel, WB | 1 |
| Lind, L | 1 |
| Lithell, H | 1 |
| Wide, L | 1 |
| Ljunghall, S | 1 |
| Biollaz, J | 1 |
| Nussberger, J | 1 |
| Waeber, B | 1 |
| Brunner, HR | 1 |
| Ena, P | 1 |
| Madeddu, P | 1 |
| Glorioso, N | 1 |
| Cerimele, D | 1 |
| Rappelli, A | 1 |
| Morandini, G | 1 |
| Spanedda, M | 1 |
| Spanedda, L | 1 |
| Kukes, VG | 2 |
| Men'shikov, VV | 2 |
| Petrunina, LA | 1 |
| Conn, J | 1 |
| Simon, NM | 1 |
| Bergan, JJ | 1 |
| Sivkov, II | 1 |
| Gneushev, ET | 1 |
| Vinogradova, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes[NCT01687998] | Phase 3 | 12,092 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Study termination due to insufficient efficacy.) | ||
| African Prospective Study for the Early Detection and Identification of Cardiovascular Disease and Hypertension (African-PREDICT Study)[NCT03292094] | 1,202 participants (Actual) | Observational | 2013-02-04 | Active, not recruiting | |||
| Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579] | Phase 4 | 8,000 participants (Anticipated) | Interventional | 2023-04-16 | Enrolling by invitation | ||
| The Effect of Low Salt Diet on CKD Progression:A Randomized Controlled Trial[NCT05716386] | 200 participants (Actual) | Interventional | 2023-02-28 | Completed | |||
| Salt Sensitive Hypertension and Striatin[NCT03683069] | Phase 4 | 400 participants (Actual) | Interventional | 2019-01-15 | Active, not recruiting | ||
| A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients[NCT04515095] | 30 participants (Actual) | Interventional | 2020-08-16 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome[NCT00658515] | Phase 3 | 15,871 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Prospective Cross-sectional Study on Prevalence of Primary Aldosteronism in Resistant Hypertension and Association With Cardiometabolic Complications[NCT04213963] | 100 participants (Anticipated) | Observational | 2011-09-01 | Recruiting | |||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| Technology Assisted Management of Uncontrolled Hypertension (TEAM-HTN): a Pilot Study[NCT03281772] | 180 participants (Anticipated) | Observational | 2017-01-24 | Recruiting | |||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients[NCT03611699] | Phase 4 | 15 participants (Actual) | Interventional | 2019-01-24 | Completed | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 857 |
| Placebo | 867 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 690 |
| Placebo | 691 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 571 |
| Placebo | 570 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline to Study Completion (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 779 |
| Placebo | 776 |
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. (NCT01687998)
Timeframe: Baseline through End of Study (Up to 4 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Evacetrapib | 437 |
| Placebo | 453 |
(NCT01687998)
Timeframe: Baseline, 3 Months
| Intervention | percent (Mean) | |
|---|---|---|
| LDL-C | HDL-C | |
| Evacetrapib | -31.12 | 133.18 |
| Placebo | 5.99 | 1.63 |
(NCT00658515)
Timeframe: At 53 Months
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Dalcetrapib (RO4607381) | 44.96 |
| Placebo | 15.60 |
(NCT00658515)
Timeframe: Throughout Study, up to 53 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dalcetrapib (RO4607381) | 226 |
| Placebo | 229 |
Number of cardiovascular events per patient per year (NCT00658515)
Timeframe: From date of randomization to first event up to 48 months
| Intervention | Event per Patient Years of Followup (Number) |
|---|---|
| Dalcetrapib (RO4607381) | 0.034050 |
| Placebo | 0.032759 |
162 reviews available for aldosterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Kidney Diseases; M | 2021 |
Mineralocorticoid receptor in cardiovascular diseases-Clinical trials and mechanistic insights.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Heart Failure; Myocardium; Receptors, Mineralocortico | 2022 |
Aldosterone and cardiovascular diseases.
Topics: Aldosterone; Atherosclerosis; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Humans; H | 2023 |
Effects of Vitamin D on Cardiovascular Risk and Oxidative Stress.
Topics: Aldosterone; Calcitriol; Calcium; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart | 2023 |
Appraising the Preclinical Evidence of the Role of the Renin-Angiotensin-Aldosterone System in Antenatal Programming of Maternal and Offspring Cardiovascular Health Across the Life Course: Moving the Field Forward: A Scientific Statement From the American
Topics: Aldosterone; American Heart Association; Cardiovascular Diseases; Female; Humans; Hypertension; Moth | 2023 |
The Effect of Aldosterone on Cardiorenal and Metabolic Systems.
Topics: Aldosterone; Cardiovascular Diseases; Essential Hypertension; Humans; Hyperaldosteronism; Hypertensi | 2023 |
Endothelial Dysfunction in Primary Aldosteronism.
Topics: Aldosterone; Cardiovascular Diseases; Cerebrovascular Disorders; Disease Progression; Humans; Hypera | 2019 |
The cardiovascular consequences of hyperaldosteronism.
Topics: Aldosterone; Blood Pressure; Cardiovascular Diseases; Humans; Hyperaldosteronism; Hypertension | 2021 |
Salt Appetite and its Effects on Cardiovascular Risk in Primary Aldosteronism.
Topics: Aldosterone; Appetite; Cardiovascular Diseases; Feeding Behavior; Heart Disease Risk Factors; Humans | 2020 |
The Effect of Extracellular Calcium Metabolism on Aldosterone Biosynthesis in Physiological and Pathological Status.
Topics: Adrenal Glands; Aldosterone; Calcium; Cardiovascular Diseases; Extracellular Space; Humans; Metaboli | 2020 |
Identifying new cellular mechanisms of mineralocorticoid receptor activation in the heart.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Mineralocorticoid Receptor Antagonists; Mineralocortic | 2021 |
Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System.
Topics: Aldosterone; Cardiovascular Diseases; Coronary Artery Disease; HIV; HIV Infections; Humans; Myocardi | 2021 |
Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines | 2021 |
DNA Methylation of the Angiotensinogen Gene,
Topics: Aldosterone; Angiotensin II; Angiotensinogen; Cardiovascular Diseases; CCAAT-Enhancer-Binding Protei | 2021 |
Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2017 |
The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall.
Topics: Adipogenesis; Adipokines; Adipose Tissue; Adiposity; Aldosterone; Animals; Blood Vessels; Cardiovasc | 2017 |
The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease.
Topics: Adipocytes; Aldosterone; Animals; Cardiovascular Diseases; Humans; Leptin; Obesity; Sex Factors | 2018 |
New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Cell Nucleus; Cytoplasm; Disea | 2018 |
Primary aldosteronism in the primary care setting.
Topics: Adrenalectomy; Aldosterone; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disorders; Huma | 2018 |
Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness.
Topics: Aldosterone; Cardiovascular Diseases; Cardiovascular System; Fibrosis; Humans; Hypertension; Models, | 2018 |
Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease.
Topics: Aldosterone; Animals; Biomarkers; Cardiovascular Diseases; Humans; Obesity; Receptors, Mineralocorti | 2018 |
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Topics: Adult; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; | 2019 |
The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Mineralocorticoid Receptor Antagonists; Protein Bindin | 2018 |
Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries.
Topics: Aldosterone; Animals; Arteries; Cardiovascular Diseases; Cardiovascular System; Heart; Humans; Recep | 2018 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep | 2019 |
Evolving research in nongenomic actions of aldosterone.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Cell Membrane; Humans; Metabol | 2013 |
Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials.
Topics: Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diet, Sodium-Restricted; Female; H | 2013 |
Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.
Topics: Aging; Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiovascular Disease | 2013 |
Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2013 |
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Disease Progression; | 2013 |
Aldosterone, organ damage and dietary salt.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Heart Ventricles; Humans; Kidney; Mineralocorticoid R | 2013 |
Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Topics: Adrenalectomy; Aldosterone; Animals; Bone Density; Bone Diseases; Calcium; Cardiovascular Diseases; | 2014 |
Aldosterone's mechanism of action: roles of lysine-specific demethylase 1, caveolin and striatin.
Topics: Aldosterone; Animals; Calmodulin-Binding Proteins; Cardiovascular Diseases; Cardiovascular System; C | 2014 |
Interactions between adrenal-regulatory and calcium-regulatory hormones in human health.
Topics: Aldosterone; Cardiovascular Diseases; Female; Humans; Hyperaldosteronism; Hyperparathyroidism, Prima | 2014 |
[Renin-aldosterone and bone metabolism].
Topics: Acute Kidney Injury; Aldosterone; Angiotensin II; Animals; Bone and Bones; Calcium; Cardiovascular D | 2014 |
Mineralocorticoids in the heart and vasculature: new insights for old hormones.
Topics: Aldosterone; Animals; Blood Vessels; Cardiovascular Diseases; Drug Design; Humans; Mineralocorticoid | 2015 |
Impact of aldosterone on osteoinductive signaling and vascular calcification.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Hyperphosphatemia; Mice; Mineralocorticoid Re | 2014 |
Aldosterone: a cardiometabolic risk hormone?
Topics: Aldosterone; Cardiovascular Diseases; Diet; Humans; Metabolic Diseases; Metabolic Syndrome; Obesity; | 2014 |
Genome-wide meta-analyses of plasma renin activity and concentration reveal association with the kininogen 1 and prekallikrein genes.
Topics: Aldosterone; Cardiovascular Diseases; Genome-Wide Association Study; Humans; Kidney Diseases; Kinino | 2015 |
Role of mineralocorticoid receptor antagonists in cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Homeostasis; Humans; Mineralocorticoid Receptor Antag | 2015 |
The renin-angiotensin-aldosterone system and calcium-regulatory hormones.
Topics: Aldosterone; Animals; Blood Pressure; Calcium; Cardiovascular Diseases; Humans; Parathyroid Hormone; | 2015 |
Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Hypertension; Metabolic Syndrome; Obesity; Receptors, | 2015 |
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Mineralocorticoid R | 2015 |
Does Aldosterone Play a Significant Role for Regulation of Vascular Tone?
Topics: Aldosterone; Animals; Calcium Signaling; Cardiovascular Diseases; Endothelium, Vascular; Humans; Mic | 2016 |
Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology.
Topics: Aging; Aldosterone; Cardiovascular Diseases; Eye Diseases; Fibrosis; Humans; Inflammation; Ion Chann | 2016 |
Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aldosterone; Cardiovascular Diseases; Hemorrhage; Hemostasis; Humans; Hyperaldosteronism; Mineraloco | 2016 |
GPER (GPR30): A Nongenomic Receptor (GPCR) for Steroid Hormones with Implications for Cardiovascular Disease and Cancer.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cell Death; Estradiol; Gonadal Steroid Hormones; Huma | 2017 |
New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Brain; Cardiovascular Diseases; Huma | 2017 |
Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Endothelium, Vascular; Epithelial Cells; Humans; Hype | 2017 |
The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.
Topics: Aldosterone; Cardiovascular Diseases; Diabetes Complications; Humans; Hypertension; Insulin Resistan | 2008 |
Circulating endothelial progenitor cells in cardiovascular disorders.
Topics: Acute Coronary Syndrome; Aldosterone; Animals; Apoptosis; Cardiovascular Diseases; Diabetes Mellitus | 2008 |
Aldosterone and cardiovascular disease.
Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular | 2009 |
Role of aldosterone and angiotensin II in insulin resistance: an update.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Humans; Insulin Resistance; Metabolic | 2009 |
Extracellular volume and aldosterone interaction in chronic kidney disease.
Topics: Aldosterone; Cardiovascular Diseases; Chronic Disease; Extracellular Fluid; Fibrosis; Humans; Inflam | 2009 |
Pharmacologic perspectives of functional selectivity by the angiotensin II type 1 receptor.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cardiomegaly; Cardiovascular D | 2008 |
Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Chymases; Diabetes Mellitus, Type 2; | 2010 |
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
Topics: Aldosterone; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hypertension; Insulin Resistanc | 2009 |
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito | 2009 |
Aldosterone and cardiovascular risk.
Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; | 2009 |
Aldosterone: effects on the kidney and cardiovascular system.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2010 |
Rapid vascular effects of steroids - a question of balance?
Topics: Aldosterone; Cardiovascular Diseases; Estradiol; Humans; Muscle, Smooth, Vascular; Signal Transducti | 2010 |
Expanding view of aldosterone action, with an emphasis on rapid action.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Cardiovascula | 2010 |
Aldosterone and cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Circadian Rhythm; Disease Models, Animal; Humans; Hyp | 2010 |
Hypertension in women: the role of progesterone and aldosterone.
Topics: Aged; Aldosterone; Androstenes; Animals; Cardiovascular Diseases; Diet, Sodium-Restricted; Estradiol | 2010 |
Aldosterone blockade in chronic kidney disease: can it improve outcome?
Topics: Aldosterone; Blood Pressure; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Hum | 2010 |
Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Topics: Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressu | 2010 |
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system.
Topics: Aldosterone; Cardiovascular Diseases; Cardiovascular System; Humans; Insulin Resistance; Kidney Fail | 2010 |
Aldosterone: a cardiovascular risk factor?
Topics: Adrenal Glands; Aldosterone; Animals; Cardiovascular Diseases; Humans; Kidney Glomerulus; Organ Spec | 2010 |
[Possibilities of laboratory diagnosis in the assessment of the activity of the renin-angiotensin-aldosterone system].
Topics: Aldosterone; Angiotensins; Cardiovascular Diseases; Clinical Laboratory Techniques; Humans; Kidney D | 2010 |
Role of genetic variation in regulation of aldosterone biosynthesis.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Genetic Variation; Humans; | 2011 |
The regulation of cell growth and survival by aldosterone.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Vessels; Brain; Cardiovascu | 2011 |
Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?
Topics: Aldosterone; Animals; Blood Pressure; Brain; Cardiovascular Diseases; Cardiovascular Physiological P | 2011 |
Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Homeostasis; Humans; | 2011 |
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Progression; Endothelium, Vascular; Humans; I | 2012 |
Targeting the aldosterone pathway in cardiovascular disease.
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delive | 2012 |
[Bone and calcium update; research of calcium metabolism on cardiovascular system update. Calcium channel blocker update].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Calcium Channels; C | 2011 |
Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Receptors, Mine | 2012 |
[Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].
Topics: Aldosterone; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Humans; Mineralocortic | 2011 |
Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Chronic Disease; Heart Failure; Hemodynamics; Humans; | 2012 |
Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Models, Animal; Heart Failure; Humans; Hypera | 2012 |
Salt, aldosterone and hypertension.
Topics: Aldosterone; Animals; Appetite; Cardiovascular Diseases; Humans; Hyperaldosteronism; Hypertension; K | 2013 |
The ubiquitous mineralocorticoid receptor: clinical implications.
Topics: Aldosterone; Cardiovascular Diseases; Glucocorticoids; Humans; Hypertension; Mineralocorticoid Recep | 2012 |
Eplerenone for the treatment of cardiovascular disorders.
Topics: Aldosterone; Animals; Cardiovascular Agents; Cardiovascular Diseases; Eplerenone; Humans; Hydrocorti | 2012 |
Aldosterone and cardiovascular disease: the heart of the matter.
Topics: Aldosterone; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiovascular Diseases; C | 2013 |
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases.
Topics: Aldosterone; Angiotensin II; Animals; Autocrine Communication; Blood Pressure; Cardiovascular Diseas | 2012 |
[Update on endocrine hypertension].
Topics: Adrenal Gland Neoplasms; Adrenocortical Adenoma; Aldosterone; Cardiovascular Diseases; Endocrine Sys | 2012 |
Vascular actions of aldosterone.
Topics: Adipocytes; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Vessels; Cardiovasc | 2013 |
Lessons from the gene expression pattern of the rat zona glomerulosa.
Topics: Adrenocorticotropic Hormone; Aldosterone; Animals; Calcium; Cardiovascular Diseases; Gene Expression | 2013 |
[Aldosterone and cardiovascular diseases, more than water and salt retention].
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Body Water; Cardiovascular Di | 2002 |
The pathophysiology of aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Brain; Cardiovascular Diseases; Eplerenone; Heart; Humans; Kidney; Mineralocor | 2002 |
Clinical implications of aldosterone blockade.
Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinica | 2002 |
The role of aldosterone receptor blockade in the management of cardiovascular disease.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Hypertension; Mine | 2002 |
Essential hypertension and left ventricular hypertrophy in cardiovascular disease: beyond overactivity of the renin-angiotensin-aldosterone-sodium system.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; | 2003 |
Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Endothelium | 2003 |
Non-genomic aldosterone action: from the cell membrane to human physiology.
Topics: Adenosine Triphosphatases; Aldosterone; Animals; Cardiovascular Diseases; Cell Membrane; Humans; Hyd | 2002 |
Eplerenone: cardiovascular protection.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Disease Models, Animal; Eplere | 2003 |
Aldosterone resurgens--letter from EPHESUS.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiovascular Diseases; Eplerenone; Humans; Inflammation | 2003 |
RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Recepto | 2003 |
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
Topics: Aldosterone; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dose-Response Relationshi | 2003 |
Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dr | 2004 |
Cardiovascular benefits of aldosterone receptor antagonists.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Female; Humans; Mineralocortic | 2003 |
Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 2004 |
[Involvement of Aldosterone and mineralocorticoid receptor in pathogenesis of cardiovascular diseases].
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Angiotensin II; Cardiovascular Diseases; F | 2004 |
Rapid non-genomic effects of aldosterone on rodent vascular function.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Endothelium, Vascular; Humans; Muscle, Smooth, Vascul | 2004 |
Rapid effects of aldosterone on vascular cells: clinical implications.
Topics: Aldosterone; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Cyclic AMP Re | 2004 |
Aldosterone blockade in cardiovascular disease.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiology; Cardiovascular Diseases; | 2004 |
[Aldosterone].
Topics: Aldosterone; Animals; Biomarkers; Cardiovascular Diseases; Cardiovascular System; Humans; Hyperaldos | 2004 |
[Renin-angiotensin-aldosterone system and natriuretic peptide system--reference to cardiovascular diseases].
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiovascular Diseases; Drug Design; Heart Fa | 2004 |
Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy.
Topics: Aldosterone; Cardiovascular Diseases; Diabetic Nephropathies; Humans; Mineralocorticoid Receptor Ant | 2004 |
Aldosterone and cardiovascular pathology: from bench to bedside.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Humans; Mineralocort | 2004 |
Aldosterone as a cardiovascular risk factor.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiovascular Diseases; Humans; Hypertension; Mineraloco | 2005 |
Aldosterone and end-organ damage.
Topics: Aldosterone; Cardiovascular Diseases; Fibrosis; Humans; Kidney Diseases; Mineralocorticoid Receptor | 2005 |
Cardiovascular effects of aldosterone.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Heart Failure; Humans; Hypertension; Mineralocorticoi | 2005 |
Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Kidney Diseases; Mineralocorticoid Receptor A | 2005 |
Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Endothelium, Vascular; Humans; | 2005 |
The mineralocorticoid receptor and oxidative stress.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Humans; Oxidative Stress; Reactive Ox | 2005 |
Effect of aldosterone and MR blockade on the brain and the kidney.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Brain; Cardiovascular Diseases; Huma | 2005 |
Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Collagen; E | 2005 |
[Recent insights into the role of aldosterone in physiology, pathology and therapy].
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Spironolactone | 2005 |
Mechanisms of mineralocorticoid action.
Topics: Aldosterone; Animals; Biological Transport; Cardiovascular Diseases; Humans; Mineralocorticoid Recep | 2005 |
Neurohumoral activation as a link to systemic manifestations of chronic lung disease.
Topics: Aldosterone; Animals; Bronchoconstriction; Cachexia; Cardiovascular Diseases; Comorbidity; Heart Rat | 2005 |
Rapid actions of aldosterone in vascular health and disease--friend or foe?
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Arteries; Cardiovascular Diseases | 2006 |
Aldosterone--a hormone of cardiovascular adaptation and maladaptation.
Topics: Aldosterone; Blood Pressure; Cardiovascular Diseases; Electrolytes; Homeostasis; Humans; Hypertensio | 2006 |
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascu | 2006 |
Mineralocorticoid receptor blockade in the protection of target organ damage.
Topics: Aldosterone; Animals; Brain; Brain Diseases; Cardiovascular Diseases; Eplerenone; Heart; Humans; Hyp | 2006 |
Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
Topics: Aldosterone; Cardiovascular Diseases; Female; Humans; Male; Mineralocorticoid Receptor Antagonists; | 2006 |
Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Humans; Mineralocorti | 2006 |
[Cardiovascular action of aldosterone].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Endothelium, Vascular; Epithelial Sodium Channels; Ep | 2006 |
[Nitric oxide].
Topics: Adiponectin; Aldosterone; Animals; Arginine; Blood Pressure; Cardiovascular Diseases; Endothelium, V | 2006 |
Hypertension and diabetes: role of the renin-angiotensin system.
Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diabetes Mell | 2006 |
Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride.
Topics: Aldosterone; Amiloride; Animals; Cardiovascular Diseases; Central Nervous System; Clinical Trials as | 2007 |
Ca2+ channel subtypes and pharmacology in the kidney.
Topics: Aldosterone; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Calcium Channel Blockers; | 2007 |
Aldosterone as a cardiovascular risk hormone.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Epithelial Cells; Humans; Models, Bio | 2007 |
The emerging role of ACE2 in physiology and disease.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Cardiovascular Diseases; Coronavirus; Female; | 2007 |
The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
Topics: Aldosterone; Animals; Atherosclerosis; Cardiovascular Diseases; Heart Failure; Humans; Hyperaldoster | 2007 |
Aldosterone and end-organ damage.
Topics: Aldosterone; Cardiovascular Diseases; Diabetes Mellitus; Endothelium, Vascular; Humans; Kidney; Kidn | 2007 |
[Role of aldosterone in oxidative stress and renal injury].
Topics: Aldosterone; Animals; Cardiovascular Diseases; Eplerenone; Humans; Mineralocorticoid Receptor Antago | 2007 |
[Molecular mechanism of cardiovascular damage induced by aldosterone].
Topics: Aldosterone; Animals; Biopterins; Cardiovascular Diseases; Cells, Cultured; Eplerenone; Humans; Mine | 2007 |
Aldosterone and vascular inflammation.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Vessels; Cardiovascular Diseases; Humans; Inflammation; | 2008 |
Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?
Topics: Aldosterone; Cardiovascular Diseases; Humans; Hypertension; Lipid Metabolism; Metabolic Syndrome; Ob | 2008 |
Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Tr | 2008 |
Renin in essential hypertension.
Topics: Adrenergic beta-Antagonists; Age Factors; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme | 1981 |
Quo vadis basic and clinical chronobiology: promise for health maintenance.
Topics: Adrenal Cortex; Alcoholism; Aldosterone; Biological Clocks; Blood Pressure; Breast Neoplasms; Cardio | 1983 |
[Effect of oral contraceptives on the circulatory system].
Topics: Aldosterone; Angiotensin II; Cardiovascular Diseases; Cerebrovascular Disorders; Contraceptives, Ora | 1980 |
Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke).
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disorders; Electrolyt | 1995 |
[Calcitonin gene-related peptide (CGRP): a vasodilator neuropeptide with many potential applications].
Topics: Aldosterone; Atrial Natriuretic Factor; Calcitonin Gene-Related Peptide; Cardiovascular Diseases; Di | 1993 |
[Polymorphism of the renin-angiotensin-aldosterone system: molecular and epidemiogenetic aspects].
Topics: Aldosterone; Angiotensinogen; Cardiovascular Diseases; Genotype; Humans; Kidney Diseases; Peptidyl-D | 1998 |
[Rigidity of large arteries and cardiovascular risk. epidemiological aspects and genetic determinants].
Topics: Aldosterone; Arteries; Cardiovascular Diseases; Elasticity; Humans; Renin-Angiotensin System; Risk F | 1999 |
Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter.
Topics: Aldosterone; Cardiovascular Diseases; Diuretics; Glomerular Filtration Rate; Humans; Natriuresis; Re | 1999 |
Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Drug Industry; Edema; Humans; Kidney Diseases; Minera | 2000 |
Identification and role of aldosterone receptors in the cardiovascular system.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Cardiovascula | 2000 |
Heart-hitting tales of salt and destruction.
Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Cardiovascular Diseases; Humans; Hyperaldosteronism; | 2000 |
Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Blood Vessels; Cardiovasc | 2000 |
Aldosterone as a determinant of cardiovascular and renal dysfunction.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Endothelium, Vascular; Fibrosis; Huma | 2001 |
Pathophysiological effects of aldosterone in cardiovascular tissues.
Topics: Adrenalectomy; Aldosterone; Animals; Cardiovascular Diseases; Cerebral Hemorrhage; Humans; Hypertens | 2001 |
Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Ca | 2000 |
[Cardiovascular complications in mineralocorticism syndrome].
Topics: Aldosterone; Cardiovascular Diseases; Humans; Hyperaldosteronism; Mineralocorticoids; Syndrome; Term | 2002 |
Nongenomic effects of aldosterone: cellular aspects and clinical implications.
Topics: Aldosterone; Animals; Baroreflex; Calcium; Cardiovascular Diseases; Humans; Ion Transport; Second Me | 2002 |
Genetic basis of cardiovascular disease--the renin-angiotensin-aldosterone system as a paradigm.
Topics: Aldosterone; Angiotensinogen; Animals; Cardiovascular Diseases; Humans; Peptidyl-Dipeptidase A; Rece | 2000 |
[Humoral factors of circulatory disorders in chronic liver diseases].
Topics: Aldosterone; Bile Acids and Salts; Blood Protein Disorders; Blood Vessels; Cardiovascular Diseases; | 1975 |
[Atrial natriuretic factor in man: physiopathological implications].
Topics: Aldosterone; Atrial Natriuretic Factor; Cardiovascular Diseases; Cardiovascular System; Humans; Kidn | 1988 |
5 trials available for aldosterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Double-Blind | 2019 |
Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
Topics: Adult; Aged; Aldosterone; Cardiovascular Diseases; Diastole; Dose-Response Relationship, Drug; Doubl | 2019 |
Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study.
Topics: Adult; Aged; Aldosterone; Black or African American; Cardiovascular Diseases; Female; Genetic Loci; | 2015 |
Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiovascula | 2002 |
[Use of the aldosterone antagonist, canrenoate potassium for treating chronic circulatory insufficiency].
Topics: Adult; Aged; Aldosterone; Canrenoic Acid; Cardiovascular Diseases; Chronic Disease; Clinical Trials | 1979 |
122 other studies available for aldosterone and Cardiovascular Diseases
| Article | Year |
|---|---|
Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP).
Topics: Aldosterone; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer | 2021 |
Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Re | 2022 |
Assessment of cardiovascular disease risk by plasma renin activity changes in patients with primary aldosteronism on mineralocorticoid receptor antagonist treatment.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Hyperaldosteronism; Mineralocorticoid Receptor Antagon | 2022 |
Aldosterone and Cardiovascular Damage: a New Lesson From an Old Study.
Topics: Aldosterone; Cardiovascular Diseases; Cardiovascular System; Humans; Mineralocorticoid Receptor Anta | 2022 |
Circulating Plasma Concentrations of ACE2 in Primary Aldosteronism and Cardiovascular Outcomes.
Topics: Adrenalectomy; Aldosterone; Angiotensin-Converting Enzyme 2; Cardiovascular Diseases; Essential Hype | 2022 |
Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Cardiovascular Diseases; Humans; Hyperaldos | 2022 |
Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Hyperaldosteronism; Hypertension; Intra-Abdominal Fat; | 2023 |
Association Between Life's Simple 7 and Biomarkers of Cardiovascular Disease: Aldosterone, Interleukin-6, C-Reactive Protein.
Topics: Adolescent; Adult; Aged; Aldosterone; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiovascular | 2023 |
Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiov | 2023 |
High plasma aldosterone concentration is associated with worse 24-h ambulatory blood pressure profile in patients with primary aldosteronism.
Topics: Adrenocorticotropic Hormone; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Car | 2023 |
Continuous hemodiafiltration as a rescue therapy for patients with cardiopulmonary failure caused by enterovirus-71: a retrospective observational study in a PICU.
Topics: Aldosterone; Angiotensin II; Cardiovascular Diseases; Catecholamines; Child, Preschool; China; Conti | 2019 |
The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats.
Topics: Aldosterone; Animals; Antioxidants; Biomarkers; Blood Pressure; Body Weight; Cardiovascular Diseases | 2020 |
FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.
Topics: Aldosterone; Animals; Bone and Bones; Cardiovascular Diseases; Disease Models, Animal; Female; Fibro | 2019 |
Mineralocorticoid Receptor Antagonists in ESKD.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Failure, Chronic; Mineralocorticoid | 2020 |
Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography.
Topics: Aged; Aldosterone; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; Female; F | 2020 |
Association of -344C/T polymorphism in the aldosterone synthase (CYP11B2) gene with cardiac and cerebrovascular events in Chinese patients with hypertension.
Topics: Adult; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Card | 2020 |
Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.
Topics: Aldosterone; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hyperaldosteronism; Hypertensi | 2021 |
Should Adrenal Venous Sampling Be Performed in PA Patients Without Apparent Adrenal Tumors?
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenalectomy; Aged; Aldosterone; Blood Specimen Collection | 2021 |
Characterization of the Renin-Angiotensin-Aldosterone System in Young Healthy Black Adults: The African Prospective Study on the Early Detection and Identification of Hypertension and Cardiovascular Disease (African-PREDICT Study).
Topics: Adult; Aldosterone; Angiotensin II; Black People; Blood Pressure; Cardiovascular Diseases; Early Dia | 2021 |
Heavy metals controlling cardiovascular diseases risk factors in myocardial infarction patients in critically environmentally heavy metal-polluted steel industrial town Mandi-Gobindgarh (India).
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldosterone; C-Reactive Protein; Cardiovascular Diseases; China; Choles | 2022 |
Myeloperoxidase, asymmetric dimethyl-arginine and the renin-angiotensin-aldosterone-system in cardiovascular risk patients: Cross-sectional findings from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.
Topics: Aged; Aldosterone; Arginine; Austria; Biomarkers; Cardiovascular Diseases; Cohort Studies; Coronary | 2017 |
Relationship and associated mechanisms between ambulatory blood pressure and clinic blood pressure with prevalent cardiovascular disease in diabetic hypertensive patients.
Topics: Aged; Aldosterone; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Body Mass In | 2017 |
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Ch | 2017 |
Renin-angiotensin-aldosterone: An inclusive, an invigorative, an interactive and an interminable system.
Topics: Aldosterone; Angiotensins; Cardiovascular Diseases; Humans; Renin; Renin-Angiotensin System | 2017 |
Aldosterone, Renin, Cardiovascular Events, and All-Cause Mortality Among African Americans: The Jackson Heart Study.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Black or African American; Body Mass Index; Cardiovascu | 2017 |
Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy.
Topics: Administration, Oral; Aldosterone; Animals; Biomarkers; Cardiovascular Diseases; Contraceptives, Ora | 2018 |
Combined Salt and Caloric Restrictions: Potential Adverse Outcomes.
Topics: Adiponectin; Aldosterone; Animal Nutritional Physiological Phenomena; Animals; Biomarkers; Blood Glu | 2017 |
Aldosterone-to-renin ratio depends on age and sex in children attending a clinic for cardiovascular risk assessment.
Topics: Adolescent; Age Factors; Aldosterone; Blood Pressure; Body Weight; Cardiovascular Diseases; Child; C | 2018 |
Primary aldosteronism and cardiovascular risk, before and after treatment.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Hyperaldosteronism; Hypertension; Risk Factors | 2018 |
Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan.
Topics: Adult; Age Distribution; Aged; Aldosterone; Cardiovascular Diseases; Cohort Studies; Comorbidity; Fe | 2018 |
Uterine fibroids and risk of hypertension: Implication of inflammation and a possible role of the renin-angiotensin-aldosterone system.
Topics: Aldosterone; Cardiovascular Diseases; Female; Humans; Hypertension; Inflammation; Leiomyoma; Renin; | 2018 |
Relationship between sodium, pentraxin-3 and aldosterone in inflammation and cardiovascular risk.
Topics: Aldosterone; C-Reactive Protein; Cardiovascular Diseases; Humans; Hypertension; Inflammation; Potass | 2018 |
New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
Topics: Age Factors; Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Congresses as Top | 2018 |
Angiotensin 1-7 suppresses angiotensin II mediated aldosterone production via JAK/STAT signaling inhibition.
Topics: Adrenocortical Carcinoma; Aldosterone; Angiotensin I; Angiotensin II; Cardiovascular Diseases; Cell | 2019 |
Human Urinary mRNA as a Biomarker of Cardiovascular Disease.
Topics: Adult; Aldosterone; Biomarkers; Cardiovascular Diseases; Extracellular Vesicles; Female; Gene Expres | 2018 |
Histone demethylase LSD1 deficiency and biological sex: impact on blood pressure and aldosterone production.
Topics: Age Factors; Albuminuria; Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Female; His | 2019 |
Aldosterone, the Mineralocorticoid Receptor and Mechanisms of Cardiovascular Disease.
Topics: Aldosterone; Cardiovascular Diseases; Gene Expression Regulation; Heart Failure; Humans; Receptors, | 2019 |
Modulation of aldosterone levels by aldosterone synthase promoter polymorphism and association with eGFR decline in patients with chronic kidney disease.
Topics: Adult; Aged; Aldosterone; Cardiovascular Diseases; Cerebrovascular Disorders; Cytochrome P-450 CYP11 | 2018 |
Subclinical Primary Aldosteronism and Cardiometabolic Disorders.
Topics: Adult; Aged; Aldosterone; Cardiovascular Diseases; Female; Global Health; Humans; Hyperaldosteronism | 2019 |
Identifying a disease-specific renin-angiotensin-aldosterone system fingerprint in patients with primary adrenal insufficiency.
Topics: Addison Disease; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Angiotensin II; Angiotensins | 2019 |
Hormonal control of trained immunity: aldosterone at the crossroad between activation of innate immunity and cardiovascular diseases.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Immunity, Innate; Lipogenesis | 2020 |
Aldosterone levels and inflammatory stimulation in essential hypertensive patients.
Topics: Adult; Aged; Aldosterone; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; C | 2013 |
Effect of early stage kidney disease on cardiac mass: comparison to post-donation renal function.
Topics: Adolescent; Adult; Aged; Aldosterone; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Echo | 2013 |
Introduction: Aldosterone and salt: heart and kidney.
Topics: Aldosterone; Cardiovascular Diseases; Congresses as Topic; Heart; Humans; Hyperaldosteronism; Kidney | 2013 |
Low sodium diet and adipokine secretion: implications for the cardiovascular system?
Topics: Adipokines; Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Di | 2014 |
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
Topics: Aldosterone; Animals; Benzimidazoles; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Fadrozole; | 2014 |
Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment.
Topics: Adult; Aged; Aldosterone; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Essential Hyperten | 2014 |
Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk.
Topics: Age Factors; Aldosterone; Angiotensin II; Blood Pressure; Cardiovascular Diseases; Cross-Sectional S | 2014 |
New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiov | 2014 |
Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.
Topics: Aged; Aldosterone; Black People; Cardiovascular Diseases; Female; Follow-Up Studies; Glomerular Filt | 2014 |
Chronic aldosterone administration causes Nox2-mediated increases in reactive oxygen species production and endothelial dysfunction in the cerebral circulation.
Topics: Age Factors; Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cerebral Arteries; Cereb | 2014 |
The role of aldosterone in the spectrum of cardiovascular and kidney disease risk: introduction.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Kidney Diseases; Periodicals as Topic; Risk | 2014 |
Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas.
Topics: Adenoma; Aldosterone; Cardiovascular Diseases; Female; Follow-Up Studies; G Protein-Coupled Inwardly | 2015 |
Low Na, high K diet and the role of aldosterone in BK-mediated K excretion.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Diet; Large-Conductance Calcium-Activated Potassium C | 2015 |
State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC
Topics: Adult; Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Female; Humans; Immunoassay; Italy; M | 2015 |
Primary aldosteronism and its various clinical scenarios.
Topics: Adult; Aged; Aldosterone; Cardiovascular Diseases; Female; Humans; Hyperaldosteronism; Hypertension; | 2015 |
Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aldosterone; Angiotensin II Type 1 Receptor Blocke | 2015 |
Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk.
Topics: Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Cross-Sectional Studies; Female; Fibroblast | 2015 |
Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease.
Topics: Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Female; Heart Atria; Humans; Kaplan-Meier Es | 2015 |
High prevalence of cardiovascular risk factors in children and adolescents with Williams-Beuren syndrome.
Topics: Adolescent; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Disea | 2015 |
Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up.
Topics: Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Echocardiography; | 2015 |
Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder.
Topics: Aldosterone; Animals; Ataxia Telangiectasia Mutated Proteins; Cardiovascular Diseases; Contraceptive | 2017 |
Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.
Topics: Aldosterone; Analysis of Variance; Animals; Cardiovascular Diseases; Disease Models, Animal; Endothe | 2016 |
Adrenal hormones and the heart.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aldosterone; Androgens; Cardiovascular Diseases; Catecholam | 2015 |
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.
Topics: Administration, Intravenous; Aged; Albumins; Aldosterone; Angiotensin II; Ascites; Cardiovascular Di | 2016 |
A Rare Case of Subclinical Primary Aldosteronism and Subclinical Cushing's Syndrome without Cardiovascular Complications.
Topics: Adrenal Gland Neoplasms; Aldosterone; Cardiovascular Diseases; Cushing Syndrome; Female; Glucocortic | 2016 |
The Renin-Angiotensin-Aldosterone System in Smokers and Non-Smokers of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study.
Topics: Aged; Aldosterone; Angiotensin I; Angiotensin II; Biomarkers; Cardiovascular Diseases; Case-Control | 2016 |
Cholecalciferol treatment downregulates renin-angiotensin system and improves endothelial function in essential hypertensive patients with hypovitaminosid D.
Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Cardiovascular Diseases; Cholecalciferol; Endoth | 2016 |
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.
Topics: Acute Coronary Syndrome; Aged; Aldosterone; Amides; Angina, Unstable; Anticholesteremic Agents; Card | 2017 |
Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Essentia | 2017 |
The failure of torcetrapib: what have we learned?
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Tr | 2008 |
Aldosterone, hypertension, and cardiovascular disease: an endless story.
Topics: Aldosterone; Cardiovascular Diseases; Chronic Disease; Comorbidity; Disease Progression; Female; Hum | 2008 |
Aldosterone and Cardiovascular Disease. Foreword.
Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular | 2009 |
Hypertension, insulin resistance, and aldosterone: sex-specific relationships.
Topics: Adolescent; Adult; Age Factors; Aldosterone; Anthropometry; Black or African American; Blood Glucose | 2009 |
Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; C-Reactive Protein; Cardiovascular Disease | 2009 |
Dihydrotestosterone stimulates aldosterone secretion by H295R human adrenocortical cells.
Topics: Adrenal Cortex; Aldosterone; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Diseases; | 2009 |
Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; C | 2009 |
Sodium chloride and aldosterone: harbingers of hypertension-related cardiovascular disease.
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Echocardiography; Humans; Hypertensio | 2009 |
Central mineralocorticoid receptors and cardiovascular disease.
Topics: Aldosterone; Animals; Blood Vessels; Brain; Cardiovascular Diseases; Hemodynamics; Humans; Inflammat | 2009 |
Moving beyond angiotensin II to also target aldosterone?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2009 |
Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Calcium; Cardiovas | 2009 |
Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.
Topics: Aged; Aldosterone; Biomarkers; Cardiovascular Diseases; Epidemiologic Methods; Female; Germany; Huma | 2010 |
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Fibrosis; Heart; Hypert | 2010 |
Aldosterone and parathyroid hormone: a complex and clinically relevant relationship.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Models, Animal; Female; Humans; Hyperaldoster | 2010 |
Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study.
Topics: Aldosterone; Cardiovascular Diseases; Coronary Angiography; Creatinine; Cystatin C; Death, Sudden, C | 2011 |
Eplerenone in mild heart failure.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor | 2011 |
Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort.
Topics: Adult; Aged; Aldosterone; California; Cardiovascular Diseases; Cohort Studies; Cross-Sectional Studi | 2011 |
Dietary sodium intake and cardiovascular mortality: controversy resolved?
Topics: Aldosterone; Blood Pressure; Cardiovascular Diseases; Cholesterol; Humans; Hypertension; Male; Middl | 2012 |
Plasma renin and outcome in the community: data from PREVEND.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Female; Heart Rate; H | 2012 |
Aldosterone is not involved in the ventricular remodeling process induced by tobacco smoke exposure.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Dietary Supplements; Echocardiography; Male; Rats; Ra | 2012 |
Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension.
Topics: Adult; Aged; Aldosterone; Asian People; Cardiovascular Diseases; Cohort Studies; Essential Hypertens | 2012 |
Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk.
Topics: Aged; Aldosterone; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Female; Heart Diseases; | 2013 |
[Aldosterone in patients with chronic circulatory insufficiency].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Humans | 1959 |
Hypoaldosteronism as a cause of hyperkalemia and syncopal attacks in a patient with complete heart block.
Topics: Aldosterone; Atrioventricular Block; Cardiovascular Diseases; Heart Block; Humans; Hyperkalemia; Hyp | 1961 |
New approaches in the study of cardiovascular disease: aldosterone, renin, hypertension and juxtaglomerular cells.
Topics: Adrenal Cortex; Aldosterone; Cardiovascular Diseases; Humans; Hypertension; Juxtaglomerular Apparatu | 1961 |
[CIRCULATORY DISORDERS AND THE KIDNEY].
Topics: Aldosterone; Blood Circulation; Blood Volume; Cardiovascular Diseases; Heart Failure; Humans; Kidney | 1964 |
[ALDOSTERONE AND SPIROLACTONES IN THE CLINICAL TREATMENT OF INTERNAL DISEASES (REVIEW OF THE LITERATURE AND ANALYSIS OF PERSONAL CASES)].
Topics: Albuminuria; Aldosterone; Blood; Cardiovascular Diseases; Drug Therapy; Humans; Hyperaldosteronism; | 1963 |
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Coronary Artery Disease; Disease Mode | 2003 |
The evolution of aldosterone antagonists.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Eplerenone; Gynecomastia; H | 2004 |
Editorial: aldosterone, normotension, and diastolic dysfunction.
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Diastole; Humans; Hyperaldosteronism | 2005 |
Aldosterone-mediated endothelial remodeling and oxidative stress.
Topics: Aldosterone; Cardiovascular Diseases; Endothelium, Vascular; Humans; Oxidative Stress | 2005 |
Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome.
Topics: Adult; Aldosterone; Atherosclerosis; Cardiovascular Diseases; Case-Control Studies; Causality; Femal | 2006 |
Aldosterone and cardiovascular disease: smoke and fire.
Topics: Aldosterone; Cardiovascular Diseases; Electrocardiography; Humans; Hyperaldosteronism; Hypertension; | 2006 |
Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study.
Topics: Aldosterone; Biomarkers; Blood Circulation; Blood Glucose; C-Reactive Protein; Cardiovascular Diseas | 2007 |
[New perspectives on vasoactive molecules regulating cardiovascular function and diseases].
Topics: Aldosterone; Bradykinin; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Endothelin | 2007 |
Cardiovascular outcomes in patients with primary aldosteronism after treatment.
Topics: Adrenalectomy; Adult; Aged; Aldosterone; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; | 2008 |
6th International Symposium on Aldosterone and ENaC: from gene to disease. 3-7 October 2007, Zermatt, Switzerland.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Epithelial Sodium Channels; Homeostasis; Humans; Inte | 2008 |
Torcetrapib and coronary events.
Topics: Aldosterone; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; | 2008 |
A symposium: Aldosterone and Antialdosterone Therapy in Cardiovascular Disease. Amsterdam, The Netherlands, August 1991.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Mineralocorticoid Receptor Antagonists | 1993 |
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Ca | 2001 |
The endothelin-aldosterone axis and cardiovascular diseases.
Topics: Adrenal Cortex; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clin | 2001 |
Aldosterone--an independent risk factor in cardiovascular disease.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Risk Factors | 2002 |
[Renin activity and adrenal functional indices in chronic circulatory insufficiency].
Topics: Adrenal Glands; Adult; Aldosterone; Cardiovascular Diseases; Chronic Disease; Coronary Disease; Epin | 1979 |
Alloxan diabetes in spontaneously hypertensive rats: gravimetric, metabolic and histopathological alterations.
Topics: Aldosterone; Animals; Body Weight; Cardiovascular Diseases; Corticosterone; Diabetes Mellitus, Exper | 1977 |
Aids in the diagnosis of hypertension.
Topics: Aldosterone; Angiotensin II; Cardiovascular Diseases; Diuretics; Humans; Hyperaldosteronism; Hyperte | 1977 |
Role of blood pressure in cardiovascular disease: the Framingham Study.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Cardiovascular Diseases; Cholesterol; Coronary Disease; De | 1975 |
Metabolic cardiovascular risk factors and the renin-aldosterone system in essential hypertension.
Topics: Adult; Aldosterone; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Creatine; Female; Gl | 1992 |
High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients.
Topics: Aldosterone; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Humans; Hypercholesterole | 1985 |
[Further observations on the cortisonic and aldosterone potentiation of the action of angiotensin in man].
Topics: Adult; Aldosterone; Angiotensin II; Betamethasone; Blood Pressure; Cardiovascular Diseases; Drug Syn | 1967 |
[Effect of hypertension on the renin-aldosterone system, renal circulation, glomerular filtration and electrolyte excretion in patients with chronic circulatory insufficiency].
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Blood Circulation; Calcium; Cardiovascular Diseases; Ch | 1970 |
A physiologic approach to curable hypertension.
Topics: Adrenal Gland Neoplasms; Aldosterone; Cardiovascular Diseases; Catecholamines; Diagnosis, Differenti | 1970 |
[Secretion of aldosterone by the adrenal glands, its blood plasma concentration and urinary excretion of 3-oxo-aldosterone in patients with chronic circulatory insufficiency].
Topics: Adrenal Glands; Adult; Aldosterone; Cardiovascular Diseases; Chronic Disease; Humans; Methods; Potas | 1970 |